<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Nature</journal-id>
        <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Nature</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0028-0836</issn>
        <issn pub-type="epub">1476-4687</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC3466113</article-id>
        <article-id pub-id-type="pmcid-ver">PMC3466113.1</article-id>
        <article-id pub-id-type="pmcaid">3466113</article-id>
        <article-id pub-id-type="pmcaiid">3466113</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS392594</article-id>
        <article-id pub-id-type="pmid">22960745</article-id>
        <article-id pub-id-type="doi">10.1038/nature11404</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS392594</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA392594</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Comprehensive genomic characterization of squamous cell lung cancers</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <collab>The Cancer Genome Atlas Research Network</collab>
          </contrib>
        </contrib-group>
        <author-notes>
          <corresp id="FN1">Correspondence to: Matthew Meyerson <email>matthew_meyerson@dfci.harvard.edu</email></corresp>
        </author-notes>
        <pub-date pub-type="epub">
          <day>09</day>
          <month>9</month>
          <year>2012</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <day>27</day>
          <month>9</month>
          <year>2012</year>
        </pub-date>
        <volume>489</volume>
        <issue>7417</issue>
        <issue-id pub-id-type="pmc-issue-id">215023</issue-id>
        <fpage>519</fpage>
        <lpage>525</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>06</day>
              <month>09</month>
              <year>2012</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>27</day>
              <month>03</month>
              <year>2013</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>27</day>
              <month>03</month>
              <year>2013</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2025-04-10 18:25:48.050">
              <day>10</day>
              <month>04</month>
              <year>2025</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <license>
            <license-p>Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: 
<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms392594.pdf"/>
        <related-article related-article-type="correction-forward" xml:lang="en" vol="491" page="288"/>
        <abstract>
          <title>Summary</title>
          <p id="P2">Lung squamous cell carcinoma (lung SqCC) is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in lung SqCC have not been comprehensively characterized and no molecularly targeted agents have been developed specifically for its treatment. As part of The Cancer Genome Atlas (TCGA), we profiled 178 lung SqCCs to provide a comprehensive landscape of genomic and epigenomic alterations. Lung SqCC is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumor. We found statistically recurrent mutations in 18 genes in including mutation of <italic toggle="yes">TP53</italic> in nearly all specimens. Previously unreported loss-of-function mutations were seen in the <italic toggle="yes">HLA-A</italic> class I major histocompatibility gene. Significantly altered pathways included <italic toggle="yes">NFE2L2/KEAP1</italic> in 34%, squamous differentiation genes in 44%, <italic toggle="yes">PI3K/AKT</italic> in 47%, and <italic toggle="yes">CDKN2A/RB1</italic> in 72% of tumors. We identified a potential therapeutic target in the majority of tumors, offering new avenues of investigation for lung SqCC treatment.</p>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec sec-type="intro" id="S1">
        <title>Introduction</title>
        <p id="P3">Lung cancer is the leading cause of cancer-related mortality worldwide, leading to an estimated 1.4 million deaths in 2010<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. The discovery of recurrent mutations in the Epidermal Growth Factor Receptor (<italic toggle="yes">EGFR</italic>) kinase as well as fusions involving the Anaplastic Lymphoma Kinase (<italic toggle="yes">ALK</italic>), has led to a dramatic change in the treatment of patients with lung adenocarcinoma, the most common type of lung cancer<sup><xref rid="R2" ref-type="bibr">2</xref>–<xref rid="R5" ref-type="bibr">5</xref></sup>. More recent data have suggested that targeting mutations in <italic toggle="yes">BRAF, AKT1, ERBB2</italic> and <italic toggle="yes">PIK3CA</italic> and fusions that involve <italic toggle="yes">ROS1</italic> and <italic toggle="yes">RET</italic> may also be successful<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup>. Unfortunately, activating mutations in <italic toggle="yes">EGFR</italic> and <italic toggle="yes">ALK</italic> fusions are typically not present in the second most common type of lung cancer, lung squamous cell carcinoma (lung SqCC),<sup><xref rid="R8" ref-type="bibr">8</xref></sup> and targeted agents developed for lung adenocarcinoma are largely ineffective against lung SqCC.</p>
        <p id="P4">Although no comprehensive genomic analysis of lung SqCCs has been reported, single-platform studies have identified regions of somatic copy number alteration in lung SqCCs, including amplification of <italic toggle="yes">SOX2, PDGFRA</italic> and <italic toggle="yes">FGFR1/WHSC1L1</italic> and deletion of <italic toggle="yes">CDKN2A</italic><sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup>. DNA sequencing studies of lung SqCCs have reported recurrent mutations in a number of genes, including <italic toggle="yes">TP53, NFE2L2, KEAP1, BAI3, FBXW7, GRM8, MUC16, RUNX1T1, STK11</italic> and <italic toggle="yes">ERBB4</italic><sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup><italic toggle="yes">. DDR2</italic> mutations and <italic toggle="yes">FGFR1</italic> amplification have been nominated as therapeutic targets<sup><xref rid="R13" ref-type="bibr">13</xref>–<xref rid="R15" ref-type="bibr">15</xref></sup>.</p>
        <p id="P5">We have conducted a comprehensive study of lung SqCCs from a large cohort of patients as part of The Cancer Genome Atlas (TCGA) project. The twin aims are to characterize the genomic/epigenomic landscape of lung SqCC and to identify potential opportunities for therapy. We report an integrated analysis based on DNA copy number, somatic exonic mutations, mRNA sequencing (RNA-seq), mRNA expression, and promoter methylation for 178 histopathologically reviewed lung SqCCs in addition to whole-genome sequencing (WGS) of 19 samples and miRNA sequencing of 159 samples (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table S1.1</xref>). Demographic and clinical data and results of the genomic analyses can be downloaded from the TCGA data portal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp">https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp</ext-link>).</p>
      </sec>
      <sec id="S2">
        <title>Samples and clinical data</title>
        <p id="P6">Tumor samples were obtained from 178 patients with previously untreated stage I–IV lung SqCC. Germline DNA was obtained from adjacent, histologically normal tissues resected at the time of surgery (n=137) or peripheral blood (n=41). All patients provided written informed consent to conduct genomic studies in accordance with local Institutional Review Boards. The demographic characteristics are described in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table S1.2</xref>. The median follow-up for the cohort was 15.8 months, and 60% of patients were alive at the time of last follow-up (data updated in November 2011). 96% of the patients had a history of tobacco use, similar to previous reports for North American lung SqCC patients<sup><xref rid="R16" ref-type="bibr">16</xref></sup>. DNA and RNA were extracted from patient specimens and were measured by several genomic assays, which included standard quality control assessments (<xref rid="SD1" ref-type="supplementary-material">Supplementary Methods, sections 2–8</xref>). A committee of experts in lung cancer pathology performed an additional review of all samples to confirm the histological subtype (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1.1</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Methods, section 1</xref>).</p>
      </sec>
      <sec id="S3">
        <title>Somatic DNA Alterations</title>
        <p id="P7">The lung SqCCs analyzed in this study display a large number and variety of DNA alterations, with a mean 360 exonic mutations, 323 altered copy number segments and 165 genomic rearrangements per tumor.</p>
        <p id="P8">Copy number alterations were analyzed using multiple platforms. Analysis of SNP 6.0 array data across the set of 178 lung SqCCs identified a high rate of copy number alteration (mean of 323 segments) when compared to other TCGA projects (as of February 1, 2012) including ovarian cancer (477 segments),<sup><xref rid="R17" ref-type="bibr">17</xref></sup> glioblastoma multiforme (282 segments),<sup><xref rid="R18" ref-type="bibr">18</xref></sup> colorectal carcinoma (213 segments), breast carcinoma (282 segments) and renal cell carcinoma (156 segments). These segments gave rise to regions of both focal and broad somatic copy number alterations (SCNAs) with a mean of 47 focal and 23 broad events per tumor (broad events defined as ≥50% of the length of the chromosome arm). There was strong concordance between the three independent copy number assays for all regions of SCNA (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figures S2.1–2.4</xref>).</p>
        <p id="P9">At the level of whole chromosome arm SCNAs, lung SqCCs exhibit many similarities to 205 cases of lung adenocarcinoma analyzed by TCGA (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S2.1a</xref>). The most striking difference between these cancers is selective amplification of chromosome 3q in lung SqCC, as has been reported<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> (p&lt;1×10<sup>−15</sup> by Fisher’s exact test). Using the SNP 6.0 array platform and GISTIC 2.0<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup>, we identified regions of significant copy number alteration (<xref rid="SD1" ref-type="supplementary-material">Supplementary Methods, section 2</xref>). There were 50 peaks of significant amplification or deletion (q&lt;0.05), several of which included SCNAs previously seen in lung SqCCs including <italic toggle="yes">SOX2, PDGFRA/KIT, EGFR, FGFR1/WHSC1L1, CCND1</italic> and <italic toggle="yes">CDKN2A</italic><sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S2.1b</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Data S2.1 and S2.2</xref>). Other peaks defined regions of SCNA reported for the first time including amplifications of chromosomal segments containing <italic toggle="yes">NFE2L2, MYC, CDK6, MDM2, BCL2L1</italic> and <italic toggle="yes">EYS</italic> and deletions of <italic toggle="yes">FOXP1, PTEN</italic> and <italic toggle="yes">NF1</italic> (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S2.1b</xref>).</p>
        <p id="P10">Whole exome sequencing of 178 lung SqCCs and matched germline DNA, targeted 193,094 exons from 18,863 genes. Mean sequencing coverage across targeted bases in was 121X with 83% of target bases above 30X coverage. We identified a total of 48,690 non-silent mutations with a mean of 228 non-silent and 360 total exonic mutations per tumor, corresponding to a mean somatic mutation rate of 8.1 mutations per megabase (Mb) and median of 8.4/Mb. That rate is higher than rates observed in other TCGA projects including acute myelogenous leukemia (0.56/Mb), breast carcinoma (1.0/Mb), ovarian cancer<sup><xref rid="R17" ref-type="bibr">17</xref></sup> (2.1/Mb), glioblastoma multiforme<sup><xref rid="R18" ref-type="bibr">18</xref></sup> (2.3/Mb) and colorectal carcinoma (3.2/Mb) (data as of February 1, 2012, p&lt;2.2 x10<sup>−16</sup> by t-test or Wilcoxon rank sum test for lung SqCC versus all others). In lung SqCC, CpG transitions and transversions were the most commonly observed mutation types, with mean rates of 9.9 and 10.7 per sequenced megabase of CpG context, respectively, for a total mutation rate of 20.6/Mb. At non-CpG sites, transversions at C:G sites were more common than transitions (7.3 vs. 2.9 per Mb; total = 10.2/Mb) and more common than transversions or transitions at A:T sites (1.5 vs. 1.3 per Mb; total = 2.8/Mb).</p>
        <p id="P11">Significantly mutated genes were identified using a modified version of the MutSig algorithm (<xref rid="SD1" ref-type="supplementary-material">Supplementary Methods, section 3</xref>)<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup>. We identified 10 genes with a false discovery rate (FDR) q value &lt;0.1 (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table S3.1</xref>): <italic toggle="yes">TP53, CDKN2A, PTEN, PIK3CA, KEAP1, MLL2, HLA-A, NFE2L2, NOTCH1</italic> and <italic toggle="yes">RB1</italic>, all of which demonstrated robust evidence of gene expression as defined by Reads Per Kilobase of exon model per Million mapped reads (RPKM) &gt;1 (<xref rid="F1" ref-type="fig">Figure 1</xref>). <italic toggle="yes">TP53</italic> mutation was observed in 81% of samples by automated analysis; visual review of sequencing reads identified an additional 9% of samples with potential mutations in regions of sub-optimal coverage or in samples with low purity. The majority of observed mutations in <italic toggle="yes">NOTCH1</italic> (8 of 17) were truncating alterations, suggesting loss-of-function, as has recently been reported for head and neck SCCs<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup>. Mutations in <italic toggle="yes">HLA-A</italic> were also almost exclusively nonsense or splice site events (7 of 8).</p>
        <p id="P12">To increase our statistical power to detect mutated genes in the setting of the observed high background mutation rate, we performed a secondary MutSig analysis only considering genes previously observed to be mutated in cancer according to the COSMIC database. This yielded 12 additional genes with FDR &lt;0.1: <italic toggle="yes">FAM123B (WTX), HRAS, FBXW7, SMARCA4, NF1, SMAD4, EGFR, APC, TSC1, BRAF, TNFAIP3</italic> and <italic toggle="yes">CREBBP</italic> (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table S3.1</xref>). Both the spectrum and the frequency of <italic toggle="yes">EGFR</italic> mutations differed from those seen in lung adenocarcinomas. The two most common alterations in lung adenocarcinoma, L858R and in-frame deletions in exon 19, were absent, whereas two L861Q mutations were detected in <italic toggle="yes">EGFR</italic>.</p>
        <p id="P13">As described in <xref rid="SD1" ref-type="supplementary-material">Supplemental Figure S3.1</xref> we verified somatic mutations by performing an independent hybrid-recapture of 76 genes in all samples. 1289 mutations were assayed and we achieved satisfactory coverage to have power to verify at 1283 positions. 1235 mutations were validated (96.2%) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S3.1</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Methods, section 3</xref>). We also verified mutation calls using WGS and RNA-sequencing data with similar results (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figures S3.1 and S4.3</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Methods, sections 3 and 4</xref>).</p>
        <p id="P14">Whole genome sequencing was performed for 19 tumor/normal pairs with a mean computed coverage of 54X. A mean of 165 somatic rearrangements was found per lung SqCC tumor pair (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S3.2</xref>), a value in excess of that reported for WGS studies of other tumor types including colorectal carcinoma (75)<sup><xref rid="R25" ref-type="bibr">25</xref></sup>, prostate carcinoma (108)<sup><xref rid="R26" ref-type="bibr">26</xref></sup>, multiple myeloma (21)<sup><xref rid="R23" ref-type="bibr">23</xref></sup>, and breast cancer (90)<sup><xref rid="R27" ref-type="bibr">27</xref></sup>. Although the majority of in-frame coding fusions detected in WGS were validated by RNA-seq, no recurrent rearrangements predicted to generate fusion proteins were identified (<xref rid="SD1" ref-type="supplementary-material">Supplementary Data S3.1 and S4.1</xref>).</p>
      </sec>
      <sec id="S4">
        <title>Somatically altered pathways</title>
        <p id="P15">Many of the somatic alterations we have identified in lung SqCCs appear to be drivers of pathways important to the initiation or progression of the cancer. Specifically, genes involved in oxidative stress response and squamous differentiation were frequently altered by mutation or SCNA. We observed mutations and copy number alterations of <italic toggle="yes">NFE2L2</italic> and <italic toggle="yes">KEAP1</italic> and/or deletion or mutation of <italic toggle="yes">CUL3</italic> in 34% of cases (<xref rid="F2" ref-type="fig">Figure 2</xref>). <italic toggle="yes">NFE2L2</italic> and <italic toggle="yes">KEAP1</italic> code for proteins that bind each other, have been shown to regulate the cell’s response to oxidative damage, chemo- and radiotherapy and are somatically altered in a variety of cancer types<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup>. We found mutations in <italic toggle="yes">NFE2L2</italic> almost exclusively in one of two KEAP1 interaction motifs, DLG or ETGE. Mutations in <italic toggle="yes">KEAP1</italic> and <italic toggle="yes">CUL3</italic> showed a pattern consistent with loss-of-function and were mutually exclusive with mutations in <italic toggle="yes">NFE2L2</italic> (<xref rid="F1" ref-type="fig">Figures 1c</xref> and <xref rid="F2" ref-type="fig">2</xref>). PARADIGM<sup><xref rid="R30" ref-type="bibr">30</xref></sup> analysis predicts that mutations in <italic toggle="yes">NFE2L2</italic> and <italic toggle="yes">KEAP1</italic> exert a significant functional impact (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S7.C.1 and S.7.C.2</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Methods, section 7</xref>).</p>
        <p id="P16">We also found alterations in genes with known roles in squamous cell differentiation in 44% of samples, including overexpression and amplification of <italic toggle="yes">SOX2</italic> and <italic toggle="yes">TP63,</italic> loss-of-function mutations in <italic toggle="yes">NOTCH1</italic>, <italic toggle="yes">NOTCH2,</italic> and <italic toggle="yes">ASCL4</italic> and focal deletions in <italic toggle="yes">FOXP1</italic> (<xref rid="F2" ref-type="fig">Figure 2</xref>). Although <italic toggle="yes">NOTCH1</italic> has been well characterized as an oncogene in hematologic cancers<sup><xref rid="R31" ref-type="bibr">31</xref></sup>, <italic toggle="yes">NOTCH1</italic> and <italic toggle="yes">NOTCH2</italic> truncating mutations have been reported in cutaneous SCCs and lung SqCCs<sup><xref rid="R32" ref-type="bibr">32</xref></sup>. Truncating mutations in <italic toggle="yes">ASCL4</italic> are the first to be reported in human cancer and may have a lineage role given the requirement for <italic toggle="yes">ASCL1</italic> for survival of small cell lung cancer cells<sup><xref rid="R33" ref-type="bibr">33</xref></sup>. Alterations in <italic toggle="yes">NOTCH1, NOTCH2</italic> and <italic toggle="yes">ASCL4</italic> were mutually exclusive and exhibited minimal overlap with amplification of <italic toggle="yes">TP63</italic> and/or <italic toggle="yes">SOX2</italic> (<xref rid="F2" ref-type="fig">Figure 2</xref>), suggesting that aberrations in those modulators of squamous cell differentiation have overlapping functional consequences.</p>
      </sec>
      <sec id="S5">
        <title>mRNA expression profiling and subtype classification</title>
        <p id="P17">Whole-transcriptome expression profiles were generated by RNA-sequencing for the entire cohort and by microarrays for a 121-sample subset. Of 20,502 genes analyzed, the mean RNA coverage indices were 19X and 6420 RPKM (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S4.1</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Methods, section 4</xref>). Previously reported lung SqCC gene expression-subtype signatures<sup><xref rid="R34" ref-type="bibr">34</xref></sup> were applied to both of the expression platforms, yielding four subtypes designated as classical (36%), basal (25%), secretory (24%) and primitive (15%). The concordance of subtypes between the two platforms was high (94% agreement) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S4.2</xref>). Significant correlations were found between the expression subtypes and genomic alterations in copy number, mutation and methylation (<xref rid="F3" ref-type="fig">Figure 3</xref>). The classical subtype was characterized by alterations in <italic toggle="yes">KEAP1</italic>, <italic toggle="yes">NFE2L2</italic>, and <italic toggle="yes">PTEN</italic>, as well as pronounced hypermethylation and chromosomal instability. The 3q26 amplicon was present in all of the subtypes, but it was most characteristic of the classical subtype, which also showed the greatest overexpression of three known oncogenes on 3q: <italic toggle="yes">SOX2, TP63</italic>, and <italic toggle="yes">PIK3CA</italic>. RNA sequencing data suggested that high expression levels of <italic toggle="yes">TP63</italic>, in samples with and without amplification of <italic toggle="yes">TP63,</italic> was associated with dominant expression of the deltaN isoform (also called p40), which lacks the N-terminal transactivation domain, compared to the longer isoform, called tap63 (89% of tumors overexpressed deltaN compared to tap63; <italic toggle="yes">p</italic>&lt;2.2e-16). That short deltaN isoform is thought to function as an oncogene<sup><xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref></sup>, and its expression was most enriched in the classical subtype. In contrast, the primitive expression-subtype more commonly exhibited <italic toggle="yes">RB1</italic> and <italic toggle="yes">PTEN</italic> alterations, and the basal expression-subtype showed <italic toggle="yes">NF1</italic> alterations (<xref rid="F3" ref-type="fig">Figure 3</xref>). Amplification of <italic toggle="yes">FGFR1</italic> and <italic toggle="yes">WHSC1L1</italic> was anti-correlated with the classical subtype and specifically with <italic toggle="yes">NFE2L2</italic> or <italic toggle="yes">KEAP1</italic> mutated samples. While <italic toggle="yes">CDKN2A</italic> alterations are common in lung SqCCs, they are not associated with any particular expression subtype (<xref rid="F3" ref-type="fig">Figure 3</xref>).</p>
        <p id="P18">Independent clustering of miRNA and methylation data indicated association with expression subtypes. The highest overall methylation was seen in the classical subtype (<xref rid="F3" ref-type="fig">Figure 3</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Figures S5.1 and S6.1</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Methods, sections 5 and 6</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Data S6.1 and S6.2</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 5.1</xref>). Integrative clustering (iCluster)<sup><xref rid="R37" ref-type="bibr">37</xref></sup> of mRNA, miRNA, methylation, SCNA, and mutation data demonstrated concordance with the mRNA expression-subtypes and associated alterations. (<xref rid="F3" ref-type="fig">Figure 3</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S7. A.1</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Methods, section 7</xref>). Independent correlation of somatic mutations, copy number alterations and gene expression signatures revealed significant subtype associations with alterations in the <italic toggle="yes">TP53, PI3K, RB1</italic> and <italic toggle="yes">NFE2L2/KEAP1</italic> pathways (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S7. B.1</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Methods, section 7</xref>).</p>
      </sec>
      <sec id="S6">
        <title>Integrated analysis of the tumor suppressor locus for <italic toggle="yes">CDKN2A</italic></title>
        <p id="P19">Integrated multi-platform analyses showed that <italic toggle="yes">CDKN2A</italic>, a known tumor suppressor gene in lung SqCC<sup><xref rid="R38" ref-type="bibr">38</xref></sup> that encodes the INK4A/p16 and ARF/p14 proteins, is inactivated in 72% of cases of lung SqCC (<xref rid="F4" ref-type="fig">Figure 4a</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Data S7.1</xref>)—by epigenetic silencing by methylation (21%), inactivating mutation (18%), exon 1β skipping (4%), and homozygous deletion (29%).</p>
        <p id="P20">Analysis of mRNA expression across the <italic toggle="yes">CDKN2A</italic> locus revealed four distinct patterns of <italic toggle="yes">p16INK4</italic> and <italic toggle="yes">ARF</italic> expression: complete absence of both <italic toggle="yes">p16INK4</italic> and <italic toggle="yes">ARF</italic> (33%); expression of high levels of both <italic toggle="yes">p16INK4</italic> and <italic toggle="yes">ARF</italic> (31%); high expression of <italic toggle="yes">ARF</italic> and absent <italic toggle="yes">p16INK4</italic> (31%); or expression of a transcript that represents a splicing of exon E1b from <italic toggle="yes">ARF</italic> with the shared E3 of <italic toggle="yes">ARF</italic> and <italic toggle="yes">p16INK4</italic>, generating a premature stop codon (4%) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S4.4</xref>). Almost all of the cases completely lacking <italic toggle="yes">p16INK4</italic> and <italic toggle="yes">ARF</italic> expression showed homozygous deletion (<xref rid="F4" ref-type="fig">Figure 4b</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplemental Data S7.1</xref>). In one case, <italic toggle="yes">p16INK4</italic> expression was detected but analysis of WGS data demonstrated an intergenic fusion event that resulted in detectable transcription between exon 1a of <italic toggle="yes">p16INK4</italic> and exon 18 of <italic toggle="yes">KIAA1797</italic> (<xref rid="F4" ref-type="fig">Figures 4b, 4c</xref>). Interestingly, combined analysis of WGS and RNA-sequencing data identified tumor suppressor gene inactivation by intra- or interchromosomal rearrangement in <italic toggle="yes">PTEN, NOTCH1, ARID1A, CTNNA2, VHL</italic> and <italic toggle="yes">NF1</italic>, in 8 additional cases (<xref rid="SD1" ref-type="supplementary-material">Supplementary Data S3.1 and S4.1</xref>).</p>
        <p id="P21">In addition to homozygous deletion, there are frequent mutational events in <italic toggle="yes">CDKN2A</italic> (<xref rid="F4" ref-type="fig">Figure 4b</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Data 7.1</xref>). These account for 45% of the 56 cases with high <italic toggle="yes">p16INK4</italic> and <italic toggle="yes">ARF</italic> expression. Furthermore, methylation of the exon 1a promoter accounts for many other cases of <italic toggle="yes">CDKN2A</italic> inactivation (70% of lung SqCCs with <italic toggle="yes">ARF</italic> expression in the absence of detectable <italic toggle="yes">p16INK4</italic>). Seven additional tumors in the high-<italic toggle="yes">ARF</italic>/low-<italic toggle="yes">INK4A</italic> group had documented mutations of <italic toggle="yes">INK4A</italic>, primarily nonsense, suggesting nonsense-mediated decay as a mechanism. Of the 28% of tumors without <italic toggle="yes">CDKN2A</italic> alterations, <italic toggle="yes">RB1</italic> mutations were identified in eight cases and <italic toggle="yes">CDK6</italic> amplification in one case (<xref rid="F4" ref-type="fig">Figure 4d</xref>).</p>
      </sec>
      <sec id="S7">
        <title>Therapeutic targets</title>
        <p id="P22">Molecularly targeted agents are now commonly used in patients with adenocarcinoma of the lung while no effective targeted agents have been developed specifically for lung SqCCs<sup><xref rid="R13" ref-type="bibr">13</xref></sup>. We analyzed our genomic data for evidence of the two common genomic alterations in adenocarcinomas of the lung: <italic toggle="yes">EGFR</italic> and <italic toggle="yes">KRAS</italic> mutation. Only one sample had a <italic toggle="yes">KRAS</italic> codon 61 mutation, and there were no exon 19 deletions or L858R mutations in <italic toggle="yes">EGFR</italic>. However, amplifications of <italic toggle="yes">EGFR</italic> were found in 7% of cases as were two instances of the L861Q <italic toggle="yes">EGFR</italic> mutation, which confers sensitivity to erlotinib and gefitinib<sup><xref rid="R39" ref-type="bibr">39</xref></sup>.</p>
        <p id="P23">The presence of new potential therapeutic targets in lung SqCC was suggested by the observation that 96% of tumors (171 of 178) contain one or more mutations in tyrosine kinases, serine/threonine kinases, PI3K catalytic and regulatory subunits, nuclear hormone receptors, G protein-coupled receptors, proteases and tyrosine phosphatases (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S7.D.1a</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Data S7.2 and S7.3</xref>). 50–77% of the mutations were predicted to have a medium or high functional impact as determined by Mutation Assessor score<sup><xref rid="R40" ref-type="bibr">40</xref></sup> (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S7.D.1a</xref>) and 39% of tyrosine and 42% of serine/threonine kinase mutations were located in the kinase domain. Many of the alterations were in known oncogenes and tumor suppressors, as defined in the COSMIC database (<xref rid="SD1" ref-type="supplementary-material">Supplementary Data S7.3</xref>).</p>
        <p id="P24">We selected potential therapeutic targets based on several features, including (i) availability of an FDA-approved targeted therapeutic agent or one under study in current clinical trials (<xref rid="SD1" ref-type="supplementary-material">Supplementary Data S7.2</xref>) (ii) confirmation of the altered allele in RNA-sequencing; and (iii) Mutation Assessor score<sup><xref rid="R40" ref-type="bibr">40</xref></sup>. Using those criteria, we identified 114 cases with somatic alteration of a potentially targetable gene (64%) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S7.D.1b</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Data S7.4</xref>). Among these we identified three families of tyrosine kinases, the ERBBs, FGFRs and JAKs, all of which were found to be mutated and/or amplified<sup><xref rid="R41" ref-type="bibr">41</xref></sup>. As discussed for <italic toggle="yes">EGFR</italic>, the mutational spectra in these potential therapeutic targets differed from those in lung adenocarcinoma (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S7.D.2</xref>).<sup><xref rid="R42" ref-type="bibr">42</xref></sup></p>
        <p id="P25">To complement a gene-centered search for potential therapeutic targets, we analyzed core cellular pathways known to represent potential therapeutic vulnerabilities: PI3K/AKT, RTK and RAS. Analysis of the 178 lung SqCCs revealed alteration in at least one of those pathways in 69% of samples after restriction of the analysis to mutations confirmed by RNA-sequencing and to amplifications associated with overexpression of the target gene (<xref rid="F5" ref-type="fig">Figure 5</xref>). Mutational events that have been curated in COSMIC are additionally shown in <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S7D.2</xref> as is the distribution of mutations, amplifications and overexpression of the genes depicted in <xref rid="F5" ref-type="fig">Figure 5C</xref>. Specifically, one of three components of the PI3K/Akt pathway (<italic toggle="yes">PIK3CA, PTEN</italic> or <italic toggle="yes">AKT3</italic>) was altered in 47% of tumors and receptor-tyrosine kinase (RTK) signaling likely altered by <italic toggle="yes">EGFR</italic> amplification, <italic toggle="yes">BRAF</italic> mutation or <italic toggle="yes">FGFR</italic> amplification or mutation in 26% of tumors. (<xref rid="F5" ref-type="fig">Figures 5</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S7.D.3</xref>). Alterations in the PI3K/Akt pathway genes were mutually exclusive with <italic toggle="yes">EGFR</italic> alterations as identified by MEMo<sup><xref rid="R43" ref-type="bibr">43</xref></sup> (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S7.D.4</xref>.). While the dependence of lung SqCC on many of these individual alterations remains to be defined functionally, this analysis suggests new areas for potential therapeutic development in this cancer.</p>
      </sec>
      <sec sec-type="discussion" id="S8">
        <title>Discussion</title>
        <p id="P26">Lung SqCCs are characterized by a high overall mutation rate of 8.1 mutations/Mb and marked genomic complexity. Similar to high-grade serous ovarian carcinoma<sup><xref rid="R17" ref-type="bibr">17</xref></sup>, almost all lung SqCCs display somatic mutation of <italic toggle="yes">TP53</italic>. There were also frequent alterations in the <italic toggle="yes">CDKN2A/RB1</italic>, <italic toggle="yes">NFE2L2/KEAP1/CUL3</italic>, <italic toggle="yes">PI3K/AKT</italic> and <italic toggle="yes">SOX2/TP63/NOTCH1</italic> pathways, providing evidence of common dysfunction in cell cycle control, response to oxidative stress, apoptotic signaling and/or squamous cell differentiation. Pathway alterations clustered according to expression-subtype in many cases, suggesting that those subtypes have a biological basis.</p>
        <p id="P27">A role for somatic mutation in the cancer hallmark of “avoiding immune destruction<sup><xref rid="R44" ref-type="bibr">44</xref></sup> is suggested by the presence of inactivating mutations in the <italic toggle="yes">HLA-A</italic> gene. Somatic loss-of-function alterations of <italic toggle="yes">HLA-A</italic> have not been reported previously in genomic studies of lung cancer. Given the recently reported efficacy of anti-Programmed Death 1 (PD1)<sup><xref rid="R45" ref-type="bibr">45</xref></sup> and anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) antibodies in NSCLC<sup><xref rid="R46" ref-type="bibr">46</xref></sup>, these <italic toggle="yes">HLA-A</italic> mutations suggest a possible role for genotypic selection of patients for immunotherapies.</p>
        <p id="P28">Targeted kinase inhibitors have been successfully used for treatment of lung adenocarcinoma but minimally so in lung SqCC. The observations reported here suggest that a detailed understanding of the possible targets in lung SqCCs may identify targeted therapeutic approaches. While <italic toggle="yes">EGFR</italic> and <italic toggle="yes">KRAS</italic> mutations, the two most common oncogenic aberrations in lung adenocarcinoma, are extremely rare in lung SqCC, alterations in the FGFR kinase family are common in lung SqCC. Lung SqCCs also share many alterations in common with head and neck squamous cell carcinomas without evidence of human papilloma virus (HPV) infection, including mutation in <italic toggle="yes">PIK3CA, PTEN, TP53, CDKN2A, NOTCH1</italic> and <italic toggle="yes">HRAS</italic><sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup>, suggesting that the biology of these two diseases may be similar.</p>
        <p id="P29">The current study has identified a potentially targetable gene or pathway alteration in the majority of the lung SqCC samples studied. The data presented here can help organize efforts to analyze lung SqCC clinical tumor specimens for a panel of specific, actionable mutations to select patients for appropriately targeted clinical trials. These data could thereby help to facilitate effective personalized therapy for this deadly disease.</p>
      </sec>
      <sec id="S9">
        <title>Methods Summary</title>
        <p id="P30">All specimens were obtained from patients with appropriate consent from the relevant institutional review board. DNA and RNA were collected from samples using the Allprep kit (Qiagen). We used commercial technology for capture and sequencing of exomes from tumor DNA and normal DNA and whole-genome shotgun sequencing. Significantly mutated genes were identified by comparing them with expectation models based on the exact measured rates of specific sequence lesions. GISTIC<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> analysis of the circular-binary-segmented Affymetrix SNP 6.0 copy number data was used to identify recurrent amplification and deletion peaks. Consensus clustering approaches were used to analyze mRNA, miRNA and methylation subtypes using previous approaches<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R41" ref-type="bibr">41</xref>,<xref rid="R44" ref-type="bibr">44</xref></sup>.</p>
      </sec>
      <sec sec-type="supplementary-material" id="S10">
        <title>Supplementary Material</title>
        <supplementary-material content-type="local-data" id="SD1" position="float" orientation="portrait">
          <label>1</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS392594-supplement-1.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" id="d37e1079" position="anchor"/>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="SD2" position="float" orientation="portrait">
          <label>2</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS392594-supplement-2.zip" mimetype="application" mime-subtype="x-zip-compressed" orientation="portrait" id="d37e1083" position="anchor"/>
        </supplementary-material>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn id="FN2">
          <label>1</label>
          <p>The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, MA 02142 USA</p>
        </fn>
        <fn id="FN3">
          <label>2</label>
          <p>Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142 USA</p>
        </fn>
        <fn id="FN4">
          <label>3</label>
          <p>Department of Systems Biology, Harvard University, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN5">
          <label>4</label>
          <p>Genetic Analysis Platform, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142 USA</p>
        </fn>
        <fn id="FN6">
          <label>5</label>
          <p>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215 USA</p>
        </fn>
        <fn id="FN7">
          <label>6</label>
          <p>Department of Pathology, Harvard Medical School, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN8">
          <label>7</label>
          <p>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z, Canada</p>
        </fn>
        <fn id="FN9">
          <label>8</label>
          <p>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94143 USA</p>
        </fn>
        <fn id="FN10">
          <label>9</label>
          <p>Belfer Institute for Applied Cancer Science, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN11">
          <label>10</label>
          <p>Department of Genetics, Harvard Medical School, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN12">
          <label>11</label>
          <p>Division of Genetics, Brigham and Women’s Hospital, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN13">
          <label>12</label>
          <p>The Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN14">
          <label>13</label>
          <p>Informatics Program, Children’s Hospital, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN15">
          <label>14</label>
          <p>Department of Dermatology, Harvard Medical School, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN16">
          <label>15</label>
          <p>Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN17">
          <label>16</label>
          <p>Institute for Pharmacogenetics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN18">
          <label>17</label>
          <p>Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN19">
          <label>18</label>
          <p>Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN20">
          <label>19</label>
          <p>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN21">
          <label>20</label>
          <p>Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN22">
          <label>21</label>
          <p>Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN23">
          <label>22</label>
          <p>Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN24">
          <label>23</label>
          <p>Department of Computer Science, University of Kentucky, Lexington, KY.40506.</p>
        </fn>
        <fn id="FN25">
          <label>24</label>
          <p>Department of Internal Medicine, Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN26">
          <label>25</label>
          <p>University of Southern California Epigenome Center, University of Southern California, Los Angeles, CA 90033 USA</p>
        </fn>
        <fn id="FN27">
          <label>26</label>
          <p>Cancer Biology Division, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231 USA</p>
        </fn>
        <fn id="FN28">
          <label>27</label>
          <p>Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 USA</p>
        </fn>
        <fn id="FN29">
          <label>28</label>
          <p>Department of Molecular Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 USA</p>
        </fn>
        <fn id="FN30">
          <label>29</label>
          <p>Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 USA</p>
        </fn>
        <fn id="FN31">
          <label>30</label>
          <p>Department of Pathology and Human Oncology &amp; Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 USA</p>
        </fn>
        <fn id="FN32">
          <label>31</label>
          <p>Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 USA</p>
        </fn>
        <fn id="FN33">
          <label>32</label>
          <p>Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN34">
          <label>33</label>
          <p>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN35">
          <label>34</label>
          <p>Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN36">
          <label>35</label>
          <p>Department of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California Santa Cruz, Santa Cruz, CA 95064 USA</p>
        </fn>
        <fn id="FN37">
          <label>36</label>
          <p>Howard Hughes Medical Institute, University of California Santa Cruz, Santa Cruz, CA 95064 USA</p>
        </fn>
        <fn id="FN38">
          <label>37</label>
          <p>Buck Institute for Age Research, Novato, CA 94945 USA</p>
        </fn>
        <fn id="FN39">
          <label>38</label>
          <p>Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA 94143 USA</p>
        </fn>
        <fn id="FN40">
          <label>39</label>
          <p>Oregon Health and Science University, Department of Molecular and Medical Genetics, Portland OR 97239 USA</p>
        </fn>
        <fn id="FN41">
          <label>40</label>
          <p>Human Genome Sequencing Center and Dan L. Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN42">
          <label>41</label>
          <p>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA</p>
        </fn>
        <fn id="FN43">
          <label>42</label>
          <p>Department of Pathology, Mayo Clinic, Rochester, MN, 55905 USA</p>
        </fn>
        <fn id="FN44">
          <label>43</label>
          <p>Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263 USA</p>
        </fn>
        <fn id="FN45">
          <label>44</label>
          <p>Department of Pathology, University of Pittsburgh Cancer Center, Pittsburgh, PA 15213 USA</p>
        </fn>
        <fn id="FN46">
          <label>45</label>
          <p>Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA 19111 USA</p>
        </fn>
        <fn id="FN47">
          <label>46</label>
          <p>Department of Pathology, University of North Carolina Medical Center, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN48">
          <label>47</label>
          <p>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 USA</p>
        </fn>
        <fn id="FN49">
          <label>48</label>
          <p>Department of Pathology, Penrose-St. Francis Health System, Colorado Springs, CO 80907 USA</p>
        </fn>
        <fn id="FN50">
          <label>49</label>
          <p>Department of Pathology and Medical Biophysics, Ontario Cancer Institute and Princess Margaret Hospital, Toronto, ON Canada</p>
        </fn>
        <fn id="FN51">
          <label>50</label>
          <p>International Genomics Consortium, Phoenix, AZ 85004 USA</p>
        </fn>
        <fn id="FN52">
          <label>51</label>
          <p>Division of Oncology, Department of Medicine and The Genome Institute, Washington University School of Medicine, St. Louis, MO 63110 USA</p>
        </fn>
        <fn id="FN53">
          <label>52</label>
          <p>Department of Surgery, University of Michigan, Ann Arbor, MI 48109 USA</p>
        </fn>
        <fn id="FN54">
          <label>53</label>
          <p>Departments of Hematology/Oncology and Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232 USA</p>
        </fn>
        <fn id="FN55">
          <label>54</label>
          <p>The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN56">
          <label>55</label>
          <p>Ontario Cancer Institute IBM Life Sciences Discovery Centre, Toronto, ON Canada</p>
        </fn>
        <fn id="FN57">
          <label>56</label>
          <p>Department of Translational Genomics, University of Cologne, Cologne, Germany</p>
        </fn>
        <fn id="FN58">
          <label>57</label>
          <p>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA</p>
        </fn>
        <fn id="FN59">
          <label>58</label>
          <p>Department of Pharmacology and Chemical Biology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232 USA</p>
        </fn>
        <fn id="FN60">
          <label>59</label>
          <p>Human Genome Sequencing Center, Baylor College of Medcine, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN61">
          <label>60</label>
          <p>Mayo Clinic College of Medicine, Rochester, MN 55905 USA</p>
        </fn>
        <fn id="FN62">
          <label>61</label>
          <p>SRA International, Fairfax, VA 22033 USA</p>
        </fn>
        <fn id="FN63">
          <label>62</label>
          <p>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN 55905 USA</p>
        </fn>
        <fn id="FN64">
          <label>63</label>
          <p>Department of Health Sciences Research, Mayo Clinic, Rochester MN 55905 USA</p>
        </fn>
        <fn id="FN65">
          <label>64</label>
          <p>Center for Individualized Medicine, Mayo Clinic, Rochester MN 55905 USA</p>
        </fn>
        <fn id="FN66">
          <label>65</label>
          <p>Department of Surgery, 600 North Wolfe Street, Baltimore, MD 21287 USA</p>
        </fn>
        <fn id="FN67">
          <label>66</label>
          <p>Department of Oncology, 600 North Wolfe Street, Baltimore, MD 21287 USA</p>
        </fn>
        <fn id="FN68">
          <label>67</label>
          <p>Department of Pathology, 600 North Wolfe Street, Baltimore, MD 21287 USA</p>
        </fn>
        <fn id="FN69">
          <label>68</label>
          <p>University of Pittsburgh, Pittsburgh, PA, 15213 USA</p>
        </fn>
        <fn id="FN70">
          <label>69</label>
          <p>Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213 USA</p>
        </fn>
        <fn id="FN71">
          <label>70</label>
          <p>Cureline, Inc., South San Francisco, CA 94080 USA</p>
        </fn>
        <fn id="FN72">
          <label>71</label>
          <p>City Clinical Oncology Dispensary, St. Petersburg, Russia</p>
        </fn>
        <fn id="FN73">
          <label>72</label>
          <p>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA</p>
        </fn>
        <fn id="FN74">
          <label>73</label>
          <p>Helen F. Graham Cancer Center, Newark, Delaware 19713 USA</p>
        </fn>
        <fn id="FN75">
          <label>74</label>
          <p>St. Joseph Medical Center, Towson, MD 21204 USA</p>
        </fn>
        <fn id="FN76">
          <label>75</label>
          <p>UNC Tissue Procurement Facility, Department of Pathology, UNC Lineberger Cancer Center, Chapel Hill, NC 27599, USA</p>
        </fn>
        <fn id="FN77">
          <label>76</label>
          <p>Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, Ontario, M5G 0A3, Canada</p>
        </fn>
        <fn id="FN78">
          <label>77</label>
          <p>Ontario Tumour Bank – Ottawa site, The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada</p>
        </fn>
        <fn id="FN79">
          <label>78</label>
          <p>Indivumed GmbH, Hamburg, Germany</p>
        </fn>
        <fn id="FN80">
          <label>79</label>
          <p>Indivumed Inc, Kensington, MD 20895, USA</p>
        </fn>
        <fn id="FN81">
          <label>80</label>
          <p>ILSBio, LLC, Chestertown, MD 21620, USA</p>
        </fn>
        <fn id="FN82">
          <label>81</label>
          <p>Ministry of Health, Hanoi, Vietnam</p>
        </fn>
        <fn id="FN83">
          <label>82</label>
          <p>Hue Central Hospital, Hue City, Vietnam</p>
        </fn>
        <fn id="FN84">
          <label>83</label>
          <p>Stanford University Medical Center, Stanford, CA 94305 USA</p>
        </fn>
        <fn id="FN85">
          <label>84</label>
          <p>Center for Minority Health Research, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN86">
          <label>85</label>
          <p>National Cancer Institute, Hanoi, Vietnam</p>
        </fn>
        <fn id="FN87">
          <label>86</label>
          <p>ILSBio LLC, Karachi, Pakistan</p>
        </fn>
        <fn id="FN88">
          <label>87</label>
          <p>The Cancer Genome Atlas Program Office, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 USA</p>
        </fn>
        <fn id="FN89">
          <label>88</label>
          <p>Center for Biomedical Informatics and Information Technology (CBIIT), National Cancer Institute, National Institutes of Health, Rockville, MD 20852 USA</p>
        </fn>
        <fn id="FN90">
          <label>89</label>
          <p>MLF Consulting, Arlington, MA 02474 USA</p>
        </fn>
        <fn id="FN91">
          <label>90</label>
          <p>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892 USA</p>
        </fn>
        <fn id="FN92">
          <label>91</label>
          <p>These authors are currently affiliated with the Institute for Applied Cancer Science, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN93">
          <label>92</label>
          <p> Max Planck Institute for Neurological Research, Cologne, Germany</p>
        </fn>
        <fn id="FN94">
          <label>93</label>
          <p> Department of Translational Cancer Genomics, Center of Integrated Oncology, University of Cologne, Cologne, Germany</p>
        </fn>
        <fn id="FN95">
          <label>94</label>
          <p>Department of Statistics and Operations Research, University of North Carolina Medical Center, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN96">
          <label>95</label>
          <p>Carolina Center for Genome Sciences, University of North Carolina Medical Center, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN97">
          <label>96</label>
          <p>ThoraxKlinik, Heidelberg University Hospital, Heidelberg, Germany.</p>
        </fn>
        <fn id="FN98" fn-type="con">
          <p><bold>Author Contributions:</bold> The TCGA research network contributed collectively to this study. Biospecimens were provided by the Tissue Source Sites and processed by the Biospecimen Core Resource. Data generation and analyses were performed by the Genome Sequencing Centers, Cancer Genome Characterization Centers, and Genome Data Analysis Centers. All data were released through the Data Coordinating Center. Project activities were coordinated by the NCI and NHGRI Project Teams.</p>
        </fn>
        <fn id="FN99">
          <p>We specifically recognize the following investigators who made substantial contributions to the project.</p>
        </fn>
        <fn id="FN100">
          <p><bold>Manuscript co-ordinators:</bold> P.S.H. and D.N.H. <bold>Data co-ordinator:</bold> M.D.W. <bold>Analysis co-ordinators:</bold> P.S.H. and N.S. <bold>DNA sequence analysis:</bold> P.S.H., M.S.L., A.S., B.H. and G.G. <bold>mRNA sequence analysis:</bold> M.D.W., J.L. and D.N.H. <bold>DNA methylation analysis:</bold> L.C., J.G.H. and L.D. <bold>Copy number analysis:</bold> A.C., G.S., N.H.P., R.K. and M.L. <bold>Pathway analysis:</bold> N.S., R.B., C.J.C., R.S., C.M., S.N., E.A.C., R.S., J.N.W. and C.S. <bold>miRNA sequence analysis:</bold> A.C. and G.R. <bold>Pathology and clinical expertise:</bold> W.D.T., B.E.J., D.A.W. and M.S.T. Project chairs: S.B.B., R.G. and M.M.</p>
        </fn>
        <fn id="FN101">
          <p><bold>Author Information:</bold> The primary and processed data used to generate the analyses presented here can be downloaded by registered users at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp">https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cghub.ucsc.edu/">https://cghub.ucsc.edu/</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/docs/publications/lusc_2012/">https://tcga-data.nci.nih.gov/docs/publications/lusc_2012/</ext-link></p>
        </fn>
      </fn-group>
      <ref-list>
        <ref id="R1">
          <label>1</label>
          <element-citation publication-type="web">
            <source>WHO Statistics</source>
            <comment>&lt;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs297/en/">http://www.who.int/mediacentre/factsheets/fs297/en/</ext-link>&gt;</comment>
            <date-in-citation>Accessed February, 2012</date-in-citation>
          </element-citation>
        </ref>
        <ref id="R2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Soda</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</article-title>
            <source>Nature</source>
            <volume>448</volume>
            <fpage>561</fpage>
            <lpage>566</lpage>
            <comment>nature05945 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/nature05945</pub-id>
            <year>2007</year>
            <pub-id pub-id-type="pmid">17625570</pub-id>
          </element-citation>
        </ref>
        <ref id="R3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Paez</surname>
                <given-names>JG</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</article-title>
            <source>Science</source>
            <volume>304</volume>
            <fpage>1497</fpage>
            <lpage>1500</lpage>
            <pub-id pub-id-type="doi">10.1126/science.10993141099314</pub-id>
            <comment>[pii]</comment>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15118125</pub-id>
          </element-citation>
        </ref>
        <ref id="R4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lynch</surname>
                <given-names>TJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</article-title>
            <source>N Engl J Med</source>
            <volume>350</volume>
            <fpage>2129</fpage>
            <lpage>2139</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa040938</pub-id>
            <comment>NEJMoa040938 [pii]</comment>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15118073</pub-id>
          </element-citation>
        </ref>
        <ref id="R5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pao</surname>
                <given-names>W</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <volume>101</volume>
            <fpage>13306</fpage>
            <lpage>13311</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.04052201010405220101</pub-id>
            <comment>[pii]</comment>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15329413</pub-id>
            <pub-id pub-id-type="pmcid">PMC516528</pub-id>
          </element-citation>
        </ref>
        <ref id="R6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Felip</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Gridelli</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Baas</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Rosell</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Stahel</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010</article-title>
            <source>Ann Oncol</source>
            <volume>22</volume>
            <fpage>1507</fpage>
            <lpage>1519</lpage>
            <comment>mdr150 [pii]</comment>
            <pub-id pub-id-type="doi">10.1093/annonc/mdr150</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21536661</pub-id>
          </element-citation>
        </ref>
        <ref id="R7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ju</surname>
                <given-names>YS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</article-title>
            <source>Genome Res</source>
            <comment>gr.133645.111 [pii]</comment>
            <pub-id pub-id-type="doi">10.1101/gr.133645.111</pub-id>
            <year>2012</year>
            <pub-id pub-id-type="pmcid">PMC3290779</pub-id>
            <pub-id pub-id-type="pmid">22194472</pub-id>
          </element-citation>
        </ref>
        <ref id="R8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rekhtman</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations</article-title>
            <source>Clin Cancer Res</source>
            <comment>1078-0432.CCR-11-2109 [pii]</comment>
            <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2109</pub-id>
            <year>2012</year>
            <pub-id pub-id-type="pmcid">PMC3487403</pub-id>
            <pub-id pub-id-type="pmid">22228640</pub-id>
          </element-citation>
        </ref>
        <ref id="R9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bass</surname>
                <given-names>AJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas</article-title>
            <source>Nat Genet</source>
            <volume>41</volume>
            <fpage>1238</fpage>
            <lpage>1242</lpage>
            <comment>ng.465 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/ng.465</pub-id>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19801978</pub-id>
            <pub-id pub-id-type="pmcid">PMC2783775</pub-id>
          </element-citation>
        </ref>
        <ref id="R10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ramos</surname>
                <given-names>AH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Amplification of chromosomal segment 4q12 in non-small cell lung cancer</article-title>
            <source>Cancer Biol Ther</source>
            <volume>8</volume>
            <fpage>2042</fpage>
            <lpage>2050</lpage>
            <comment>9764 [pii]</comment>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19755855</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/cbt.8.21.9764</pub-id>
            <pub-id pub-id-type="pmcid">PMC2833355</pub-id>
          </element-citation>
        </ref>
        <ref id="R11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shibata</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <volume>105</volume>
            <fpage>13568</fpage>
            <lpage>13573</lpage>
            <comment>0806268105 [pii]</comment>
            <pub-id pub-id-type="doi">10.1073/pnas.0806268105</pub-id>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18757741</pub-id>
            <pub-id pub-id-type="pmcid">PMC2533230</pub-id>
          </element-citation>
        </ref>
        <ref id="R12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kan</surname>
                <given-names>Z</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Diverse somatic mutation patterns and pathway alterations in human cancers</article-title>
            <source>Nature</source>
            <volume>466</volume>
            <fpage>869</fpage>
            <lpage>873</lpage>
            <comment>nature09208 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/nature09208</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20668451</pub-id>
          </element-citation>
        </ref>
        <ref id="R13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hammerman</surname>
                <given-names>PS</given-names>
              </name>
              <name name-style="western">
                <surname>Sos</surname>
                <given-names>ML</given-names>
              </name>
              <name name-style="western">
                <surname>Ramos</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Xu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer</article-title>
            <source>Cancer Discovery</source>
            <volume>1</volume>
            <year>2011</year>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8274.CD-11-0005</pub-id>
            <pub-id pub-id-type="pmcid">PMC3274752</pub-id>
            <pub-id pub-id-type="pmid">22328973</pub-id>
          </element-citation>
        </ref>
        <ref id="R14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Weiss</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer</article-title>
            <source>Sci Transl Med</source>
            <volume>2</volume>
            <fpage>62ra93</fpage>
            <comment>2/62/62ra93 [pii]</comment>
            <pub-id pub-id-type="doi">10.1126/scitranslmed.3001451</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmcid">PMC3990281</pub-id>
            <pub-id pub-id-type="pmid">21160078</pub-id>
          </element-citation>
        </ref>
        <ref id="R15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Dutt</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer</article-title>
            <source>PLoS One</source>
            <volume>6</volume>
            <fpage>e20351</fpage>
            <pub-id pub-id-type="doi">10.1371/journal.pone.0020351</pub-id>
            <comment>PONE-D-11-00027 [pii]</comment>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21666749</pub-id>
            <pub-id pub-id-type="pmcid">PMC3110189</pub-id>
          </element-citation>
        </ref>
        <ref id="R16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kenfield</surname>
                <given-names>SA</given-names>
              </name>
              <name name-style="western">
                <surname>Wei</surname>
                <given-names>EK</given-names>
              </name>
              <name name-style="western">
                <surname>Stampfer</surname>
                <given-names>MJ</given-names>
              </name>
              <name name-style="western">
                <surname>Rosner</surname>
                <given-names>BA</given-names>
              </name>
              <name name-style="western">
                <surname>Colditz</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Comparison of aspects of smoking among the four histological types of lung cancer</article-title>
            <source>Tob Control</source>
            <volume>17</volume>
            <fpage>198</fpage>
            <lpage>204</lpage>
            <comment>tc.2007.022582 [pii]</comment>
            <pub-id pub-id-type="doi">10.1136/tc.2007.022582</pub-id>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18390646</pub-id>
            <pub-id pub-id-type="pmcid">PMC3044470</pub-id>
          </element-citation>
        </ref>
        <ref id="R17">
          <label>17</label>
          <element-citation publication-type="journal">
            <article-title>Integrated genomic analyses of ovarian carcinoma</article-title>
            <source>Nature</source>
            <volume>474</volume>
            <fpage>609</fpage>
            <lpage>615</lpage>
            <comment>nature10166 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/nature10166</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21720365</pub-id>
            <pub-id pub-id-type="pmcid">PMC3163504</pub-id>
          </element-citation>
        </ref>
        <ref id="R18">
          <label>18</label>
          <element-citation publication-type="journal">
            <article-title>Comprehensive genomic characterization defines human glioblastoma genes and core pathways</article-title>
            <source>Nature</source>
            <volume>455</volume>
            <fpage>1061</fpage>
            <lpage>1068</lpage>
            <comment>nature07385 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/nature07385</pub-id>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18772890</pub-id>
            <pub-id pub-id-type="pmcid">PMC2671642</pub-id>
          </element-citation>
        </ref>
        <ref id="R19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tonon</surname>
                <given-names>G</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>High-resolution genomic profiles of human lung cancer</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <volume>102</volume>
            <fpage>9625</fpage>
            <lpage>9630</lpage>
            <comment>0504126102 [pii]</comment>
            <pub-id pub-id-type="doi">10.1073/pnas.0504126102</pub-id>
            <year>2005</year>
            <pub-id pub-id-type="pmid">15983384</pub-id>
            <pub-id pub-id-type="pmcid">PMC1160520</pub-id>
          </element-citation>
        </ref>
        <ref id="R20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Beroukhim</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The landscape of somatic copy-number alteration across human cancers</article-title>
            <source>Nature</source>
            <volume>463</volume>
            <fpage>899</fpage>
            <lpage>905</lpage>
            <comment>nature08822 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/nature08822</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20164920</pub-id>
            <pub-id pub-id-type="pmcid">PMC2826709</pub-id>
          </element-citation>
        </ref>
        <ref id="R21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Mermel</surname>
                <given-names>CH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers</article-title>
            <source>Genome Biol</source>
            <volume>12</volume>
            <fpage>R41</fpage>
            <comment>gb-2011-12-4-r41 [pii]</comment>
            <pub-id pub-id-type="doi">10.1186/gb-2011-12-4-r41</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21527027</pub-id>
            <pub-id pub-id-type="pmcid">PMC3218867</pub-id>
          </element-citation>
        </ref>
        <ref id="R22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Stransky</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The mutational landscape of head and neck squamous cell carcinoma</article-title>
            <source>Science</source>
            <volume>333</volume>
            <fpage>1157</fpage>
            <lpage>1160</lpage>
            <comment>science.1208130 [pii]</comment>
            <pub-id pub-id-type="doi">10.1126/science.1208130</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21798893</pub-id>
            <pub-id pub-id-type="pmcid">PMC3415217</pub-id>
          </element-citation>
        </ref>
        <ref id="R23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Chapman</surname>
                <given-names>MA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Initial genome sequencing and analysis of multiple myeloma</article-title>
            <source>Nature</source>
            <volume>471</volume>
            <fpage>467</fpage>
            <lpage>472</lpage>
            <comment>nature09837 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/nature09837</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21430775</pub-id>
            <pub-id pub-id-type="pmcid">PMC3560292</pub-id>
          </element-citation>
        </ref>
        <ref id="R24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Agrawal</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1</article-title>
            <source>Science</source>
            <volume>333</volume>
            <fpage>1154</fpage>
            <lpage>1157</lpage>
            <comment>science.1206923 [pii]</comment>
            <pub-id pub-id-type="doi">10.1126/science.1206923</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21798897</pub-id>
            <pub-id pub-id-type="pmcid">PMC3162986</pub-id>
          </element-citation>
        </ref>
        <ref id="R25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bass</surname>
                <given-names>AJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion</article-title>
            <source>Nat Genet</source>
            <volume>43</volume>
            <fpage>964</fpage>
            <lpage>968</lpage>
            <comment>ng.936 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/ng.936</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21892161</pub-id>
            <pub-id pub-id-type="pmcid">PMC3802528</pub-id>
          </element-citation>
        </ref>
        <ref id="R26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Berger</surname>
                <given-names>MF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The genomic complexity of primary human prostate cancer</article-title>
            <source>Nature</source>
            <volume>470</volume>
            <fpage>214</fpage>
            <lpage>220</lpage>
            <comment>nature09744 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/nature09744</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21307934</pub-id>
            <pub-id pub-id-type="pmcid">PMC3075885</pub-id>
          </element-citation>
        </ref>
        <ref id="R27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Stephens</surname>
                <given-names>PJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Complex landscapes of somatic rearrangement in human breast cancer genomes</article-title>
            <source>Nature</source>
            <volume>462</volume>
            <fpage>1005</fpage>
            <lpage>1010</lpage>
            <comment>nature08645 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/nature08645</pub-id>
            <year>2009</year>
            <pub-id pub-id-type="pmid">20033038</pub-id>
            <pub-id pub-id-type="pmcid">PMC3398135</pub-id>
          </element-citation>
        </ref>
        <ref id="R28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer</article-title>
            <source>PLoS Med</source>
            <volume>3</volume>
            <fpage>e420</fpage>
            <comment>06-PLME-RA-0322R2 [pii]</comment>
            <pub-id pub-id-type="doi">10.1371/journal.pmed.0030420</pub-id>
            <year>2006</year>
            <pub-id pub-id-type="pmid">17020408</pub-id>
            <pub-id pub-id-type="pmcid">PMC1584412</pub-id>
          </element-citation>
        </ref>
        <ref id="R29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Bodas</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Wakabayashi</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Bunz</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Biswal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance</article-title>
            <source>Antioxid Redox Signal</source>
            <volume>13</volume>
            <fpage>1627</fpage>
            <lpage>1637</lpage>
            <pub-id pub-id-type="doi">10.1089/ars.2010.3219</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20446773</pub-id>
            <pub-id pub-id-type="pmcid">PMC3541552</pub-id>
          </element-citation>
        </ref>
        <ref id="R30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Vaske</surname>
                <given-names>CJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Inference of patient-specific pathway activities from multidimensional cancer genomics data using PARADIGM</article-title>
            <source>Bioinformatics</source>
            <volume>26</volume>
            <fpage>i237</fpage>
            <lpage>245</lpage>
            <comment>btq182 [pii]</comment>
            <pub-id pub-id-type="doi">10.1093/bioinformatics/btq182</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20529912</pub-id>
            <pub-id pub-id-type="pmcid">PMC2881367</pub-id>
          </element-citation>
        </ref>
        <ref id="R31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Aster</surname>
                <given-names>JC</given-names>
              </name>
              <name name-style="western">
                <surname>Blacklow</surname>
                <given-names>SC</given-names>
              </name>
              <name name-style="western">
                <surname>Pear</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies</article-title>
            <source>J Pathol</source>
            <volume>223</volume>
            <fpage>262</fpage>
            <lpage>273</lpage>
            <pub-id pub-id-type="doi">10.1002/path.2789</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">20967796</pub-id>
            <pub-id pub-id-type="pmcid">PMC2996483</pub-id>
          </element-citation>
        </ref>
        <ref id="R32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>NJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <volume>108</volume>
            <fpage>17761</fpage>
            <lpage>17766</lpage>
            <comment>1114669108 [pii]</comment>
            <pub-id pub-id-type="doi">10.1073/pnas.1114669108</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">22006338</pub-id>
            <pub-id pub-id-type="pmcid">PMC3203814</pub-id>
          </element-citation>
        </ref>
        <ref id="R33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Osada</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Tatematsu</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Yatabe</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Horio</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Takahashi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features</article-title>
            <source>Cancer Res</source>
            <volume>65</volume>
            <fpage>10680</fpage>
            <lpage>10685</lpage>
            <comment>65/23/10680 [pii]</comment>
            <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1404</pub-id>
            <year>2005</year>
            <pub-id pub-id-type="pmid">16322211</pub-id>
          </element-citation>
        </ref>
        <ref id="R34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wilkerson</surname>
                <given-names>MD</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types</article-title>
            <source>Clin Cancer Res</source>
            <volume>16</volume>
            <fpage>4864</fpage>
            <lpage>4875</lpage>
            <comment>1078-0432.CCR-10-0199 [pii]</comment>
            <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0199</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20643781</pub-id>
            <pub-id pub-id-type="pmcid">PMC2953768</pub-id>
          </element-citation>
        </ref>
        <ref id="R35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bishop</surname>
                <given-names>JA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma</article-title>
            <source>Mod Pathol</source>
            <comment>modpathol2011173 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/modpathol.2011.173</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">22056955</pub-id>
          </element-citation>
        </ref>
        <ref id="R36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Massion</surname>
                <given-names>PP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Significance of p63 amplification and overexpression in lung cancer development and prognosis</article-title>
            <source>Cancer Res</source>
            <volume>63</volume>
            <fpage>7113</fpage>
            <lpage>7121</lpage>
            <year>2003</year>
            <pub-id pub-id-type="pmid">14612504</pub-id>
          </element-citation>
        </ref>
        <ref id="R37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shen</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Olshen</surname>
                <given-names>AB</given-names>
              </name>
              <name name-style="western">
                <surname>Ladanyi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis</article-title>
            <source>Bioinformatics</source>
            <volume>25</volume>
            <fpage>2906</fpage>
            <lpage>2912</lpage>
            <comment>btp543 [pii]</comment>
            <pub-id pub-id-type="doi">10.1093/bioinformatics/btp543</pub-id>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19759197</pub-id>
            <pub-id pub-id-type="pmcid">PMC2800366</pub-id>
          </element-citation>
        </ref>
        <ref id="R38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wikman</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Kettunen</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer</article-title>
            <source>Expert Rev Anticancer Ther</source>
            <volume>6</volume>
            <fpage>515</fpage>
            <lpage>530</lpage>
            <pub-id pub-id-type="doi">10.1586/14737140.6.4.515</pub-id>
            <year>2006</year>
            <pub-id pub-id-type="pmid">16613540</pub-id>
          </element-citation>
        </ref>
        <ref id="R39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kancha</surname>
                <given-names>RK</given-names>
              </name>
              <name name-style="western">
                <surname>Peschel</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Duyster</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors</article-title>
            <source>J Thorac Oncol</source>
            <volume>6</volume>
            <fpage>387</fpage>
            <lpage>392</lpage>
            <pub-id pub-id-type="doi">10.1097/JTO.0b013e3182021f3e</pub-id>
            <comment>01243894-201102000-00020 [pii]</comment>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21252719</pub-id>
          </element-citation>
        </ref>
        <ref id="R40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Reva</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Antipin</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Sander</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Predicting the functional impact of protein mutations: application to cancer genomics</article-title>
            <source>Nucleic Acids Res</source>
            <volume>39</volume>
            <fpage>e118</fpage>
            <comment>gkr407 [pii]</comment>
            <pub-id pub-id-type="doi">10.1093/nar/gkr407</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21727090</pub-id>
            <pub-id pub-id-type="pmcid">PMC3177186</pub-id>
          </element-citation>
        </ref>
        <ref id="R41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Govindan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer</article-title>
            <source>J Thorac Oncol</source>
            <volume>5</volume>
            <fpage>S433</fpage>
            <pub-id pub-id-type="doi">10.1097/JTO.0b013e3181fd6fe1</pub-id>
            <comment>01243894-201012002-00001 [pii]</comment>
            <year>2010</year>
            <pub-id pub-id-type="pmid">21102234</pub-id>
            <pub-id pub-id-type="pmcid">PMC3203685</pub-id>
          </element-citation>
        </ref>
        <ref id="R42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ding</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Somatic mutations affect key pathways in lung adenocarcinoma</article-title>
            <source>Nature</source>
            <volume>455</volume>
            <fpage>1069</fpage>
            <lpage>1075</lpage>
            <comment>nature07423 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/nature07423</pub-id>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18948947</pub-id>
            <pub-id pub-id-type="pmcid">PMC2694412</pub-id>
          </element-citation>
        </ref>
        <ref id="R43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ciriello</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Cerami</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Sander</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Schultz</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Mutual exclusivity analysis identifies oncogenic network modules</article-title>
            <source>Genome Res</source>
            <volume>22</volume>
            <fpage>398</fpage>
            <lpage>406</lpage>
            <comment>gr.125567.111 [pii]</comment>
            <pub-id pub-id-type="doi">10.1101/gr.125567.111</pub-id>
            <year>2012</year>
            <pub-id pub-id-type="pmid">21908773</pub-id>
            <pub-id pub-id-type="pmcid">PMC3266046</pub-id>
          </element-citation>
        </ref>
        <ref id="R44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hanahan</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Weinberg</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Hallmarks of cancer: the next generation</article-title>
            <source>Cell</source>
            <volume>144</volume>
            <fpage>646</fpage>
            <lpage>674</lpage>
            <comment>S0092-8674(11)00127-9 [pii]</comment>
            <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21376230</pub-id>
          </element-citation>
        </ref>
        <ref id="R45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Brahmer</surname>
                <given-names>JR</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates</article-title>
            <source>J Clin Oncol</source>
            <volume>28</volume>
            <fpage>3167</fpage>
            <lpage>3175</lpage>
            <comment>JCO.2009.26.7609 [pii]</comment>
            <pub-id pub-id-type="doi">10.1200/JCO.2009.26.7609</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20516446</pub-id>
            <pub-id pub-id-type="pmcid">PMC4834717</pub-id>
          </element-citation>
        </ref>
        <ref id="R46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lynch</surname>
                <given-names>TJ</given-names>
              </name>
              <name name-style="western">
                <surname>Bondarenko</surname>
                <given-names>IN</given-names>
              </name>
              <name name-style="western">
                <surname>Luft</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Serwatowski</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Barlesi</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Chacko</surname>
                <given-names>RT</given-names>
              </name>
              <name name-style="western">
                <surname>Sebastian</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Siegel</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Cuillerot</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC)</article-title>
            <source>J Clin Oncol</source>
            <volume>28</volume>
            <fpage>7531</fpage>
            <year>2010</year>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2011.38.4032</pub-id>
            <pub-id pub-id-type="pmid">22547592</pub-id>
          </element-citation>
        </ref>
      </ref-list>
      <app-group>
        <app id="APP1">
          <title>TCGA Network Authors and Affiliations</title>
          <sec id="S12">
            <title>Genome Sequencing Centers</title>
            <p id="P31"><italic toggle="yes">Broad Institute –</italic> Peter S Hammerman(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>), Michael S. Lawrence(<xref ref-type="fn" rid="FN2">1</xref>), Douglas Voet(<xref ref-type="fn" rid="FN2">1</xref>), Rui Jing(<xref ref-type="fn" rid="FN2">1</xref>), Kristian Cibulskis(<xref ref-type="fn" rid="FN2">1</xref>), Andrey Sivachenko(<xref ref-type="fn" rid="FN2">1</xref>), Petar Stojanov(<xref ref-type="fn" rid="FN2">1</xref>), Aaron McKenna(<xref ref-type="fn" rid="FN2">1</xref>), Eric S Lander(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN3">2</xref>,<xref ref-type="fn" rid="FN4">3</xref>), Stacey Gabriel(<xref ref-type="fn" rid="FN5">4</xref>), Gad Getz(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN5">4</xref>), Carrie Sougnez(<xref ref-type="fn" rid="FN5">4</xref>), Marcin Imielinski (<xref ref-type="fn" rid="FN2">1</xref>), Elena Helman (<xref ref-type="fn" rid="FN2">1</xref>), Bryan Hernandez (<xref ref-type="fn" rid="FN2">1</xref>), Nam H. Pho (<xref ref-type="fn" rid="FN2">1</xref>), Matthew Meyerson(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>,<xref ref-type="fn" rid="FN7">6</xref>)</p>
          </sec>
          <sec id="S13">
            <title>Genome Characterization Centers</title>
            <p id="P32"><italic toggle="yes">BC Cancer Agency –</italic> Andy Chu(<xref ref-type="fn" rid="FN8">7</xref>), Hye-Jung E. Chun(<xref ref-type="fn" rid="FN8">7</xref>), Andrew J. Mungall(<xref ref-type="fn" rid="FN8">7</xref>), Erin Pleasance(<xref ref-type="fn" rid="FN8">7</xref>), A. Gordon Robertson(<xref ref-type="fn" rid="FN8">7</xref>), Payal Sipahimalani(<xref ref-type="fn" rid="FN8">7</xref>), Dominik Stoll(<xref ref-type="fn" rid="FN8">7</xref>), Miruna Balasundaram(<xref ref-type="fn" rid="FN8">7</xref>), Inanc Birol(<xref ref-type="fn" rid="FN8">7</xref>), Yaron S.N. Butterfield(<xref ref-type="fn" rid="FN8">7</xref>), Eric Chuah(<xref ref-type="fn" rid="FN8">7</xref>), Robin J.N. Coope(<xref ref-type="fn" rid="FN8">7</xref>), Richard Corbett(<xref ref-type="fn" rid="FN8">7</xref>), Noreen Dhalla(<xref ref-type="fn" rid="FN8">7</xref>), Ranabir Guin(<xref ref-type="fn" rid="FN8">7</xref>), An He(<xref ref-type="fn" rid="FN8">7</xref>), Carrie Hirst(<xref ref-type="fn" rid="FN8">7</xref>), Martin Hirst(<xref ref-type="fn" rid="FN8">7</xref>), Robert A. Holt(<xref ref-type="fn" rid="FN8">7</xref>), Darlene Lee(<xref ref-type="fn" rid="FN8">7</xref>), Haiyan I. Li(<xref ref-type="fn" rid="FN8">7</xref>), Michael Mayo(<xref ref-type="fn" rid="FN8">7</xref>), Richard A. Moore(<xref ref-type="fn" rid="FN8">7</xref>), Karen Mungall(<xref ref-type="fn" rid="FN8">7</xref>), Ka Ming Nip(<xref ref-type="fn" rid="FN8">7</xref>), Adam Olshen(<xref ref-type="fn" rid="FN9">8</xref>), Jacqueline E. Schein(<xref ref-type="fn" rid="FN8">7</xref>), Jared R. Slobodan(<xref ref-type="fn" rid="FN8">7</xref>), Angela Tam(<xref ref-type="fn" rid="FN8">7</xref>), Nina Thiessen(<xref ref-type="fn" rid="FN8">7</xref>), Richard Varhol(<xref ref-type="fn" rid="FN8">7</xref>), Thomas Zeng(<xref ref-type="fn" rid="FN8">7</xref>), Yongjun Zhao(<xref ref-type="fn" rid="FN8">7</xref>), Steven J.M. Jones(<xref ref-type="fn" rid="FN8">7</xref>), Marco A. Marra(<xref ref-type="fn" rid="FN8">7</xref>) <italic toggle="yes">Broad Institute –</italic> Gordon Saksena(<xref ref-type="fn" rid="FN2">1</xref>), Andrew D. Cherniack(<xref ref-type="fn" rid="FN2">1</xref>), Stephen E. Schumacher(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>), Barbara Tabak(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>), Scott L. Carter(<xref ref-type="fn" rid="FN2">1</xref>), Nam H. Pho(<xref ref-type="fn" rid="FN2">1</xref>), Huy Nguyen(<xref ref-type="fn" rid="FN2">1</xref>), Robert C. Onofrio(<xref ref-type="fn" rid="FN5">4</xref>), Andrew Crenshaw(<xref ref-type="fn" rid="FN2">1</xref>), Kristin Ardlie(<xref ref-type="fn" rid="FN5">4</xref>), Rameen Beroukhim(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>), Wendy Winckler(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN5">4</xref>), Peter S Hammerman (<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>) Gad Getz(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN5">4</xref>), Matthew Meyerson(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>,<xref ref-type="fn" rid="FN7">6</xref>)<italic toggle="yes">, Brigham and Women’s Hospital and Harvard Medical School –</italic> Alexei Protopopov (<xref ref-type="fn" rid="FN10">9</xref>,<xref ref-type="fn" rid="FN92">91</xref>), Jianhua Zhang (<xref ref-type="fn" rid="FN10">9</xref>,<xref ref-type="fn" rid="FN92">91</xref>), Angela Hadjipanayis (<xref ref-type="fn" rid="FN11">10</xref>,<xref ref-type="fn" rid="FN12">11</xref>), Semin Lee (<xref ref-type="fn" rid="FN13">12</xref>), Ruibin Xi (<xref ref-type="fn" rid="FN13">12</xref>), Lixing Yang(<xref ref-type="fn" rid="FN13">12</xref>), Xiaojia Ren(<xref ref-type="fn" rid="FN10">9</xref>,<xref ref-type="fn" rid="FN11">10</xref>,<xref ref-type="fn" rid="FN12">11</xref>), Hailei Zhang (<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN10">9</xref>), Sachet Shukla (<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN10">9</xref>), Peng-Chieh Chen (<xref ref-type="fn" rid="FN11">10</xref>,<xref ref-type="fn" rid="FN12">11</xref>), Psalm Haseley (<xref ref-type="fn" rid="FN12">11</xref>,<xref ref-type="fn" rid="FN13">12</xref>), Eunjung Lee (<xref ref-type="fn" rid="FN12">11</xref>,<xref ref-type="fn" rid="FN13">12</xref>), Lynda Chin (<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>,<xref ref-type="fn" rid="FN10">9</xref>,<xref ref-type="fn" rid="FN15">14</xref>,<xref ref-type="fn" rid="FN92">91</xref>), Peter J. Park (<xref ref-type="fn" rid="FN12">11</xref>,<xref ref-type="fn" rid="FN13">12</xref>,<xref ref-type="fn" rid="FN14">13</xref>), Raju Kucherlapati (<xref ref-type="fn" rid="FN11">10</xref>,<xref ref-type="fn" rid="FN12">11</xref>), <italic toggle="yes">Memorial Sloan-Kettering Cancer Center (TCGA Pilot Phase only)</italic> Nicholas D. Socci (<xref ref-type="fn" rid="FN28">27</xref>), Yupu Liang (<xref ref-type="fn" rid="FN28">27</xref>), Nikolaus Schultz (<xref ref-type="fn" rid="FN28">27</xref>), Laetitia Borsu (<xref ref-type="fn" rid="FN28">27</xref>), Alex E. Lash (<xref ref-type="fn" rid="FN28">27</xref>), Agnes Viale (<xref ref-type="fn" rid="FN28">27</xref>), Chris Sander (<xref ref-type="fn" rid="FN28">27</xref>), Marc Ladanyi (<xref ref-type="fn" rid="FN29">28</xref>, <xref ref-type="fn" rid="FN31">30</xref>), <italic toggle="yes">University of North Carolina, Chapel Hill</italic>: J. Todd Auman(<xref ref-type="fn" rid="FN16">15</xref>,<xref ref-type="fn" rid="FN17">16</xref>), Katherine A. Hoadley(<xref ref-type="fn" rid="FN18">17</xref>,<xref ref-type="fn" rid="FN19">18</xref>,<xref ref-type="fn" rid="FN20">19</xref>), Matthew D. Wilkerson(<xref ref-type="fn" rid="FN20">19</xref>), Yan Shi(<xref ref-type="fn" rid="FN20">19</xref>), Christina Liquori (<xref ref-type="fn" rid="FN20">19</xref>), Shaowu Meng(<xref ref-type="fn" rid="FN20">19</xref>), Ling Li(<xref ref-type="fn" rid="FN20">19</xref>), Yidi J. Turman(<xref ref-type="fn" rid="FN20">19</xref>), Michael D. Topal(<xref ref-type="fn" rid="FN19">18</xref>,<xref ref-type="fn" rid="FN20">19</xref>), Donghui Tan(<xref ref-type="fn" rid="FN21">20</xref>), Scot Waring(<xref ref-type="fn" rid="FN20">19</xref>), Elizabeth Buda(<xref ref-type="fn" rid="FN20">19</xref>), Jesse Walsh(<xref ref-type="fn" rid="FN20">19</xref>), Corbin D. Jones(<xref ref-type="fn" rid="FN22">21</xref>), Piotr A. Mieczkowski(<xref ref-type="fn" rid="FN18">17</xref>), Darshan Singh(<xref ref-type="fn" rid="FN25">24</xref>), Junyuan Wu(<xref ref-type="fn" rid="FN20">19</xref>), Anisha Gulabani(<xref ref-type="fn" rid="FN20">19</xref>), Peter Dolina(<xref ref-type="fn" rid="FN20">19</xref>), Tom Bodenheimer(<xref ref-type="fn" rid="FN20">19</xref>), Alan P. Hoyle(<xref ref-type="fn" rid="FN20">19</xref>), Janae V. Simons(<xref ref-type="fn" rid="FN20">19</xref>), Matthew G. Soloway(<xref ref-type="fn" rid="FN20">19</xref>), Lisle E. Mose(<xref ref-type="fn" rid="FN19">18</xref>), Stuart R. Jefferys(<xref ref-type="fn" rid="FN19">18</xref>), Saianand Balu(<xref ref-type="fn" rid="FN20">19</xref>), Brian D. O’Connor(<xref ref-type="fn" rid="FN20">19</xref>), Jan F. Prins(<xref ref-type="fn" rid="FN23">22</xref>), Jinze Liu (<xref ref-type="fn" rid="FN24">23</xref>), Derek Y. Chiang(<xref ref-type="fn" rid="FN18">17</xref>,<xref ref-type="fn" rid="FN20">19</xref>), D. Neil Hayes(<xref ref-type="fn" rid="FN20">19</xref>,<xref ref-type="fn" rid="FN25">24</xref>), Charles M. Perou(<xref ref-type="fn" rid="FN18">17</xref>,<xref ref-type="fn" rid="FN19">18</xref>,<xref ref-type="fn" rid="FN20">19</xref>), <italic toggle="yes">University of Southern California / Johns Hopkins –</italic> Leslie Cope (<xref ref-type="fn" rid="FN27">26</xref>), Ludmila Danilova (<xref ref-type="fn" rid="FN27">26</xref>), Daniel J. Weisenberger(<xref ref-type="fn" rid="FN26">25</xref>), Dennis T. Maglinte(<xref ref-type="fn" rid="FN26">25</xref>), Fei Pan(<xref ref-type="fn" rid="FN26">25</xref>), David J. Van Den Berg(<xref ref-type="fn" rid="FN26">25</xref>), Timothy Triche Jr(<xref ref-type="fn" rid="FN26">25</xref>), Stephen B. Baylin(<xref ref-type="fn" rid="FN27">26</xref>), &amp; Peter W. Laird(<xref ref-type="fn" rid="FN26">25</xref>)</p>
          </sec>
          <sec id="S14" sec-type="methods">
            <title>Genome Data Analysis Centers</title>
            <p id="P33"><italic toggle="yes">Broad Institute –</italic> Gad Getz(<xref ref-type="fn" rid="FN2">1</xref>), Michael Noble(<xref ref-type="fn" rid="FN2">1</xref>), Doug Voet(<xref ref-type="fn" rid="FN2">1</xref>), Gordon Saksena(<xref ref-type="fn" rid="FN2">1</xref>), Nils Gehlenborg(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN13">12</xref>), Daniel DiCara(<xref ref-type="fn" rid="FN2">1</xref>), Jinhua Zhang(<xref ref-type="fn" rid="FN10">9</xref>, <xref ref-type="fn" rid="FN92">91</xref>), Hailei Zhang(<xref ref-type="fn" rid="FN2">1</xref>), Chang-Jiun Wu(<xref ref-type="fn" rid="FN6">5</xref>,<xref ref-type="fn" rid="FN92">91</xref>), Spring Yingchun Liu(<xref ref-type="fn" rid="FN2">1</xref>), Michael S. Lawrence(<xref ref-type="fn" rid="FN2">1</xref>), Lihua Zou(<xref ref-type="fn" rid="FN2">1</xref>), Andrey Sivachenko(<xref ref-type="fn" rid="FN2">1</xref>), Pei Lin(<xref ref-type="fn" rid="FN2">1</xref>), Petar Stojanov(<xref ref-type="fn" rid="FN2">1</xref>), Rui Jing(<xref ref-type="fn" rid="FN2">1</xref>), Juok Cho(<xref ref-type="fn" rid="FN2">1</xref>), Marc-Danie Nazaire(<xref ref-type="fn" rid="FN2">1</xref>), Jim Robinson(<xref ref-type="fn" rid="FN2">1</xref>), Helga Thorvaldsdottir(<xref ref-type="fn" rid="FN2">1</xref>), Jill Mesirov(<xref ref-type="fn" rid="FN2">1</xref>), Peter J. Park(<xref ref-type="fn" rid="FN12">11</xref>,<xref ref-type="fn" rid="FN13">12</xref>,<xref ref-type="fn" rid="FN14">13</xref>), Lynda Chin(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>,<xref ref-type="fn" rid="FN10">9</xref>,<xref ref-type="fn" rid="FN15">14</xref>,<xref ref-type="fn" rid="FN92">91</xref>) <italic toggle="yes">Memorial Sloan-Kettering Cancer Center –</italic> Nikolaus Schultz(<xref ref-type="fn" rid="FN28">27</xref>), Rileen Sinha(<xref ref-type="fn" rid="FN28">27</xref>), Giovanni Ciriello(<xref ref-type="fn" rid="FN28">27</xref>), Ethan Cerami(<xref ref-type="fn" rid="FN28">27</xref>), Benjamin Gross(<xref ref-type="fn" rid="FN28">27</xref>), Anders Jacobsen(<xref ref-type="fn" rid="FN28">27</xref>), Jianjiong Gao(<xref ref-type="fn" rid="FN28">27</xref>), B. Arman Aksoy(<xref ref-type="fn" rid="FN28">27</xref>), Nils Weinhold(<xref ref-type="fn" rid="FN28">27</xref>), Ricardo Ramirez(<xref ref-type="fn" rid="FN28">27</xref>), Barry S. Taylor(<xref ref-type="fn" rid="FN28">27</xref>), Yevgeniy Antipin(<xref ref-type="fn" rid="FN28">27</xref>), Boris Reva(<xref ref-type="fn" rid="FN28">27</xref>), Ronglai Shen(<xref ref-type="fn" rid="FN30">29</xref>), Qianxing Mo(<xref ref-type="fn" rid="FN30">29</xref>), Venkatraman Seshan(<xref ref-type="fn" rid="FN30">29</xref>), Paul K Paik (<xref ref-type="fn" rid="FN32">31</xref>), Marc Ladanyi(<xref ref-type="fn" rid="FN29">28</xref>, <xref ref-type="fn" rid="FN31">30</xref>), Chris Sander(<xref ref-type="fn" rid="FN28">27</xref>) <italic toggle="yes">The University of Texas MD Anderson Cancer Center –</italic> Rehan Akbani(<xref ref-type="fn" rid="FN33">32</xref>), Nianxiang Zhang(<xref ref-type="fn" rid="FN33">32</xref>), Bradley M. Broom(<xref ref-type="fn" rid="FN33">32</xref>), Tod Casasent(<xref ref-type="fn" rid="FN33">32</xref>), Anna Unruh(<xref ref-type="fn" rid="FN33">32</xref>), Chris Wakefield(<xref ref-type="fn" rid="FN33">32</xref>), R. Craig Cason (<xref ref-type="fn" rid="FN34">33</xref>), Keith A. Baggerly(<xref ref-type="fn" rid="FN33">32</xref>), John N. Weinstein(<xref ref-type="fn" rid="FN33">32</xref>,<xref ref-type="fn" rid="FN35">34</xref>), <italic toggle="yes">University of California, Santa Cruz / Buck Institute –</italic> David Haussler(<xref ref-type="fn" rid="FN36">35</xref>,<xref ref-type="fn" rid="FN37">36</xref>), Christopher C. Benz(<xref ref-type="fn" rid="FN38">37</xref>), Joshua M. Stuart(<xref ref-type="fn" rid="FN36">35</xref>), Jingchun Zhu(<xref ref-type="fn" rid="FN36">35</xref>), Christopher Szeto(<xref ref-type="fn" rid="FN36">35</xref>), Gary K. Scott(<xref ref-type="fn" rid="FN38">37</xref>), &amp; Christina Yau(<xref ref-type="fn" rid="FN38">37</xref>). Sam Ng(<xref ref-type="fn" rid="FN36">35</xref>), Ted Goldstein(<xref ref-type="fn" rid="FN36">35</xref>), Peter Waltman(<xref ref-type="fn" rid="FN36">35</xref>), Artem Sokolov(<xref ref-type="fn" rid="FN36">35</xref>), Kyle Ellrott(<xref ref-type="fn" rid="FN36">35</xref>), Eric A. Collisson(<xref ref-type="fn" rid="FN39">38</xref>), Daniel Zerbino(<xref ref-type="fn" rid="FN36">35</xref>), Christopher Wilks(<xref ref-type="fn" rid="FN36">35</xref>), Singer Ma(<xref ref-type="fn" rid="FN36">35</xref>), Brian Craft(<xref ref-type="fn" rid="FN36">35</xref>), <italic toggle="yes">University of North Carolina, Chapel Hill</italic>: Matthew D. Wilkerson(<xref ref-type="fn" rid="FN20">19</xref>), J. Todd Auman(<xref ref-type="fn" rid="FN16">15</xref>,<xref ref-type="fn" rid="FN17">16</xref>), Katherine A. Hoadley(<xref ref-type="fn" rid="FN18">17</xref>,<xref ref-type="fn" rid="FN19">18</xref>,<xref ref-type="fn" rid="FN20">19</xref>), Ying Du(<xref ref-type="fn" rid="FN20">19</xref>), Christopher Cabanski (<xref ref-type="fn" rid="FN20">19</xref>), Vonn Walter (<xref ref-type="fn" rid="FN20">19</xref>), Darshan Singh (<xref ref-type="fn" rid="FN20">19</xref>) Junyuan Wu(<xref ref-type="fn" rid="FN20">19</xref>), Anisha Gulabani(<xref ref-type="fn" rid="FN20">19</xref>), Tom Bodenheimer(<xref ref-type="fn" rid="FN20">19</xref>), Alan P. Hoyle(<xref ref-type="fn" rid="FN20">19</xref>), Janae V. Simons(<xref ref-type="fn" rid="FN20">19</xref>), Matthew G. Soloway(<xref ref-type="fn" rid="FN20">19</xref>), Lisle E. Mose(<xref ref-type="fn" rid="FN19">18</xref>), Stuart R. Jefferys(<xref ref-type="fn" rid="FN19">18</xref>), Saianand Balu(<xref ref-type="fn" rid="FN20">19</xref>), J.S. Marron (<xref ref-type="fn" rid="FN95">94</xref>), Yufeng Liu (<xref ref-type="fn" rid="FN96">95</xref>), Kai Wang (<xref ref-type="fn" rid="FN24">23</xref>), Jinze Liu (<xref ref-type="fn" rid="FN24">23</xref>), Jan F. Prins(<xref ref-type="fn" rid="FN20">19</xref>), D. Neil Hayes(<xref ref-type="fn" rid="FN20">19</xref>,<xref ref-type="fn" rid="FN25">24</xref>), Charles M. Perou(<xref ref-type="fn" rid="FN18">17</xref>,<xref ref-type="fn" rid="FN19">18</xref>,<xref ref-type="fn" rid="FN20">19</xref>), <italic toggle="yes">Baylor College of Medicine</italic> - Chad J Creighton(<xref ref-type="fn" rid="FN41">40</xref>), Yiqun Zhang(<xref ref-type="fn" rid="FN41">40</xref>)</p>
          </sec>
          <sec id="S15">
            <title>Pathology Committee</title>
            <p id="P34">William D. Travis (<xref ref-type="fn" rid="FN42">41</xref>), Natasha Rekhtman(<xref ref-type="fn" rid="FN42">41</xref>), Joanne Yi(<xref ref-type="fn" rid="FN43">42</xref>), Marie C. Aubry(<xref ref-type="fn" rid="FN43">42</xref>), Richard Cheney(<xref ref-type="fn" rid="FN44">43</xref>), Sanja Dacic(<xref ref-type="fn" rid="FN45">44</xref>), Douglas Flieder(<xref ref-type="fn" rid="FN46">45</xref>), William Funkhouser(<xref ref-type="fn" rid="FN47">46</xref>), Peter Illei(<xref ref-type="fn" rid="FN48">47</xref>), Jerome Myers (<xref ref-type="fn" rid="FN49">48</xref>), Ming Sound Tsao(<xref ref-type="fn" rid="FN50">49</xref>)</p>
          </sec>
          <sec id="S16">
            <title>Biospecimen Core Resources</title>
            <p id="P35"><italic toggle="yes">International Genomics Consortium –</italic> Robert Penny(<xref ref-type="fn" rid="FN51">50</xref>), David Mallery (<xref ref-type="fn" rid="FN51">50</xref>), Troy Shelton(<xref ref-type="fn" rid="FN51">50</xref>), Martha Hatfield(<xref ref-type="fn" rid="FN51">50</xref>), Scott Morris(<xref ref-type="fn" rid="FN51">50</xref>), Peggy Yena(<xref ref-type="fn" rid="FN51">50</xref>), Candace Shelton(<xref ref-type="fn" rid="FN51">50</xref>), Mark Sherman(<xref ref-type="fn" rid="FN51">50</xref>),&amp; Joseph Paulauskis(<xref ref-type="fn" rid="FN51">50</xref>)</p>
          </sec>
          <sec id="S17">
            <title>Disease working group</title>
            <p id="P36">Matthew Meyerson(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>,<xref ref-type="fn" rid="FN7">6</xref>), Stephen B. Baylin(<xref ref-type="fn" rid="FN27">26</xref>), Ramaswamy Govindan(<xref ref-type="fn" rid="FN52">51</xref>), Rehan Akbani(<xref ref-type="fn" rid="FN33">32</xref>), Ijeoma Azodo(<xref ref-type="fn" rid="FN61">60</xref>), David Beer(<xref ref-type="fn" rid="FN53">52</xref>), Ron Bose(<xref ref-type="fn" rid="FN52">51</xref>), Lauren A. Byers (<xref ref-type="fn" rid="FN55">54</xref>) David Carbone(<xref ref-type="fn" rid="FN54">53</xref>), Li-Wei Chang (<xref ref-type="fn" rid="FN52">51</xref>), Derek Chiang(<xref ref-type="fn" rid="FN18">17</xref>,<xref ref-type="fn" rid="FN20">19</xref>), Andy Chu(<xref ref-type="fn" rid="FN8">7</xref>), Elizabeth Chun(<xref ref-type="fn" rid="FN8">7</xref>), Eric Collisson(<xref ref-type="fn" rid="FN39">38</xref>), Leslie Cope(<xref ref-type="fn" rid="FN27">26</xref>), Chad J Creighton(<xref ref-type="fn" rid="FN41">40</xref>), Ludmila Danilova(<xref ref-type="fn" rid="FN27">26</xref>), Li Ding(<xref ref-type="fn" rid="FN52">51</xref>), Gad Getz(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN5">4</xref>), Peter S Hammerman(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>), D Neil Hayes(<xref ref-type="fn" rid="FN20">19</xref>,<xref ref-type="fn" rid="FN24">23</xref>), Bryan Hernandez(<xref ref-type="fn" rid="FN2">1</xref>), James Herman(<xref ref-type="fn" rid="FN27">26</xref>), John Heymach(<xref ref-type="fn" rid="FN55">54</xref>), Cristiane Ida(<xref ref-type="fn" rid="FN43">42</xref>), Marcin Imielinski(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN7">6</xref>), Bruce Johnson(<xref ref-type="fn" rid="FN6">5</xref>), Igor Jurisica(<xref ref-type="fn" rid="FN56">55</xref>), Jacob Kaufman(<xref ref-type="fn" rid="FN54">53</xref>), Farhad Kosari(<xref ref-type="fn" rid="FN61">60</xref>), Raju Kucherlapati(<xref ref-type="fn" rid="FN11">10</xref>,<xref ref-type="fn" rid="FN12">11</xref>), David Kwiatkowski(<xref ref-type="fn" rid="FN6">5</xref>), Marc Ladanyi(<xref ref-type="fn" rid="FN29">28</xref>, <xref ref-type="fn" rid="FN31">30</xref>), Michael Lawrence(<xref ref-type="fn" rid="FN2">1</xref>), Christopher A Maher(<xref ref-type="fn" rid="FN52">51</xref>), Andy Mungall(<xref ref-type="fn" rid="FN8">7</xref>), Sam Ng(<xref ref-type="fn" rid="FN36">35</xref>), William Pao(<xref ref-type="fn" rid="FN54">53</xref>), Martin Peifer(<xref ref-type="fn" rid="FN57">56</xref>, <xref ref-type="fn" rid="FN93">92</xref>), Robert Penny(<xref ref-type="fn" rid="FN51">50</xref>), Gordon Robertson(<xref ref-type="fn" rid="FN8">7</xref>), Valerie Rusch(<xref ref-type="fn" rid="FN58">57</xref>) Chris Sander(<xref ref-type="fn" rid="FN28">27</xref>), Nikolaus Schultz(<xref ref-type="fn" rid="FN28">27</xref>), Ronglai Shen(<xref ref-type="fn" rid="FN30">29</xref>), Jill Siegfried(<xref ref-type="fn" rid="FN59">58</xref>), Rileen Sinha(<xref ref-type="fn" rid="FN28">27</xref>), Andrey Sivachenko(<xref ref-type="fn" rid="FN2">1</xref>), Carrie Sougnez(<xref ref-type="fn" rid="FN5">4</xref>), Dominik Stoll(<xref ref-type="fn" rid="FN8">7</xref>), Joshua Stuart(<xref ref-type="fn" rid="FN36">35</xref>), Roman K Thomas(<xref ref-type="fn" rid="FN57">56</xref>, <xref ref-type="fn" rid="FN93">92</xref>, <xref ref-type="fn" rid="FN94">93</xref>), Sandra Tomaszek(<xref ref-type="fn" rid="FN61">60</xref>), Ming-Sound Tsao(<xref ref-type="fn" rid="FN50">49</xref>), William D Travis(<xref ref-type="fn" rid="FN42">41</xref>), Charles Vaske(<xref ref-type="fn" rid="FN36">35</xref>), John N Weinstein(<xref ref-type="fn" rid="FN33">32</xref>,<xref ref-type="fn" rid="FN35">34</xref>), Daniel Weisenberger(<xref ref-type="fn" rid="FN26">25</xref>), David Wheeler(<xref ref-type="fn" rid="FN60">59</xref>), Dennis A Wigle(<xref ref-type="fn" rid="FN61">60</xref>), Matthew D Wilkerson(<xref ref-type="fn" rid="FN20">19</xref>), Christopher Wilks(<xref ref-type="fn" rid="FN26">25</xref>), Ping Yang(<xref ref-type="fn" rid="FN61">60</xref>), Jianjua (John) Zhang(<xref ref-type="fn" rid="FN10">9</xref>)</p>
          </sec>
          <sec id="S18" sec-type="methods">
            <title>Data Coordination Center</title>
            <p id="P37">Mark A. Jensen(<xref ref-type="fn" rid="FN62">61</xref>), Robert Sfeir(<xref ref-type="fn" rid="FN62">61</xref>), Ari B. Kahn(<xref ref-type="fn" rid="FN62">61</xref>), Anna L. Chu(<xref ref-type="fn" rid="FN62">61</xref>), Prachi Kothiyal(<xref ref-type="fn" rid="FN62">61</xref>), Zhining Wang(<xref ref-type="fn" rid="FN62">61</xref>), Eric E. Snyder(<xref ref-type="fn" rid="FN62">61</xref>), Joan Pontius(<xref ref-type="fn" rid="FN62">61</xref>), Todd D. Pihl(<xref ref-type="fn" rid="FN62">61</xref>), Brenda Ayala(<xref ref-type="fn" rid="FN62">61</xref>), Mark Backus(<xref ref-type="fn" rid="FN62">61</xref>), Jessica Walton(<xref ref-type="fn" rid="FN62">61</xref>), Julien Baboud(<xref ref-type="fn" rid="FN62">61</xref>), Dominique L. Berton(<xref ref-type="fn" rid="FN62">61</xref>), Matthew C. Nicholls(<xref ref-type="fn" rid="FN62">61</xref>), Deepak Srinivasan(<xref ref-type="fn" rid="FN62">61</xref>), Rohini Raman(<xref ref-type="fn" rid="FN62">61</xref>), Stanley Girshik(<xref ref-type="fn" rid="FN62">61</xref>), Peter A. Kigonya(<xref ref-type="fn" rid="FN62">61</xref>), Shelley Alonso(<xref ref-type="fn" rid="FN62">61</xref>), Rashmi N. Sanbhadti(<xref ref-type="fn" rid="FN62">61</xref>), Sean P. Barletta(<xref ref-type="fn" rid="FN62">61</xref>), John M. Greene(<xref ref-type="fn" rid="FN62">61</xref>) &amp; David A. Pot(<xref ref-type="fn" rid="FN62">61</xref>)</p>
          </sec>
          <sec id="S19">
            <title>Tissue Source Sites</title>
            <p id="P38">Ming Tsao(<xref ref-type="fn" rid="FN50">49</xref>), Bizhan Bandarchi-Chamkhaleh(<xref ref-type="fn" rid="FN50">49</xref>), Jeff Boyd(<xref ref-type="fn" rid="FN46">45</xref>), JoEllen Weaver(<xref ref-type="fn" rid="FN46">45</xref>), Dennis A. Wigle (<xref ref-type="fn" rid="FN61">60</xref>), Ijeoma A. Azodo(<xref ref-type="fn" rid="FN61">60</xref>), Sandra C. Tomaszek(<xref ref-type="fn" rid="FN61">60</xref>), Marie Christine Aubry(<xref ref-type="fn" rid="FN63">62</xref>), Christiane M. Ida(<xref ref-type="fn" rid="FN63">62</xref>), Ping Yang(<xref ref-type="fn" rid="FN64">63</xref>), Farhad Kosari(<xref ref-type="fn" rid="FN65">64</xref>), Malcolm V. Brock(<xref ref-type="fn" rid="FN66">65</xref>), Kristen Rogers(<xref ref-type="fn" rid="FN66">65</xref>), Marian Rutledge(<xref ref-type="fn" rid="FN67">66</xref>), Travis Brown(<xref ref-type="fn" rid="FN66">65</xref>), Beverly Lee(<xref ref-type="fn" rid="FN67">66</xref>), James Shin(<xref ref-type="fn" rid="FN68">67</xref>), Dante Trusty(<xref ref-type="fn" rid="FN68">67</xref>), Rajiv Dhir(<xref ref-type="fn" rid="FN69">68</xref>), Jill M. Siegfried(<xref ref-type="fn" rid="FN70">69</xref>), Olga Potapova(<xref ref-type="fn" rid="FN71">70</xref>), Konstantin V. Fedosenko(<xref ref-type="fn" rid="FN72">71</xref>), Elena Nemirovich-Danchenko(<xref ref-type="fn" rid="FN71">70</xref>), Valerie Rusch(<xref ref-type="fn" rid="FN58">57</xref>), Maureen Zakowski(<xref ref-type="fn" rid="FN73">72</xref>), Mary V. Iacocca (<xref ref-type="fn" rid="FN74">73</xref>), Jennifer Brown(<xref ref-type="fn" rid="FN74">73</xref>), Brenda Rabeno(<xref ref-type="fn" rid="FN74">73</xref>), Christine Czerwinski(<xref ref-type="fn" rid="FN74">73</xref>), Nicholas Petrelli(<xref ref-type="fn" rid="FN74">73</xref>), Zhen Fan(<xref ref-type="fn" rid="FN75">74</xref>), Nicole Todaro(<xref ref-type="fn" rid="FN75">74</xref>), John Eckman(<xref ref-type="fn" rid="FN49">48</xref>), Jerome Myers(<xref ref-type="fn" rid="FN49">48</xref>), W. Kimryn Rathmell(<xref ref-type="fn" rid="FN20">19</xref>), Leigh B. Thorne(<xref ref-type="fn" rid="FN76">75</xref>), Mei Huang(<xref ref-type="fn" rid="FN76">75</xref>), Lori Boice(<xref ref-type="fn" rid="FN76">75</xref>), Ashley Hill(<xref ref-type="fn" rid="FN20">19</xref>), Robert Penny(<xref ref-type="fn" rid="FN51">50</xref>), David Mallery(<xref ref-type="fn" rid="FN51">50</xref>), Erin Curley(<xref ref-type="fn" rid="FN51">50</xref>), Candace Shelton(<xref ref-type="fn" rid="FN51">50</xref>), Peggy Yena(<xref ref-type="fn" rid="FN51">50</xref>), Carl Morrison(<xref ref-type="fn" rid="FN44">43</xref>), Carmelo Gaudioso(<xref ref-type="fn" rid="FN44">43</xref>), John M.S. Bartlett(<xref ref-type="fn" rid="FN77">76</xref>), Sugy Kodeeswaran(<xref ref-type="fn" rid="FN77">76</xref>), Brent Zanke(<xref ref-type="fn" rid="FN77">76</xref>), Harman Sekhon(<xref ref-type="fn" rid="FN78">77</xref>), Kerstin David(<xref ref-type="fn" rid="FN79">78</xref>), Hartmut Juhl(<xref ref-type="fn" rid="FN80">79</xref>), Xuan Van Le(<xref ref-type="fn" rid="FN81">80</xref>), Bernard Kohl(<xref ref-type="fn" rid="FN81">80</xref>), Richard Thorp(<xref ref-type="fn" rid="FN81">80</xref>), Nguyen Viet Tien(<xref ref-type="fn" rid="FN82">81</xref>), Nguyen Van Bang(<xref ref-type="fn" rid="FN83">82</xref>), Howard Sussman(<xref ref-type="fn" rid="FN84">83</xref>), Bui Duc Phu(<xref ref-type="fn" rid="FN83">82</xref>), Richard Hajek(<xref ref-type="fn" rid="FN85">84</xref>), Nguyen Phi Hung(<xref ref-type="fn" rid="FN86">85</xref>) &amp; Khurram Z. Khan(<xref ref-type="fn" rid="FN87">86</xref>), Thomas Muley (<xref ref-type="fn" rid="FN97">96</xref>)</p>
          </sec>
          <sec id="S20">
            <title>Project Team</title>
            <p id="P39"><italic toggle="yes">National Cancer Institute –</italic> Kenna R. Mills Shaw(<xref ref-type="fn" rid="FN88">87</xref>), Margi Sheth (<xref ref-type="fn" rid="FN88">87</xref>), Liming Yang (<xref ref-type="fn" rid="FN88">87</xref>), Ken Buetow(<xref ref-type="fn" rid="FN89">88</xref>), Tanja Davidsen(<xref ref-type="fn" rid="FN89">88</xref>), John A. Demchok(<xref ref-type="fn" rid="FN88">87</xref>), Greg Eley(<xref ref-type="fn" rid="FN89">88</xref>), Martin Ferguson(<xref ref-type="fn" rid="FN90">89</xref>), Laura A. L. Dillon(<xref ref-type="fn" rid="FN88">87</xref>) &amp; Carl Schaefer(<xref ref-type="fn" rid="FN89">88</xref>) <italic toggle="yes">National Human Genome Research Institute</italic>: Mark S. Guyer(<xref ref-type="fn" rid="FN91">90</xref>), Bradley A. Ozenberger(<xref ref-type="fn" rid="FN91">90</xref>), Jacqueline D. Palchik(<xref ref-type="fn" rid="FN91">90</xref>), Jane Peterson(<xref ref-type="fn" rid="FN91">90</xref>), Heidi J. Sofia(<xref ref-type="fn" rid="FN91">90</xref>), &amp; Elizabeth Thomson(<xref ref-type="fn" rid="FN91">90</xref>)</p>
            <sec id="S21">
              <title>Writing Committee</title>
              <p id="P40">Peter S Hammerman(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>), D Neil Hayes(<xref ref-type="fn" rid="FN20">19</xref>,<xref ref-type="fn" rid="FN24">23</xref>), Matthew D Wilkerson(<xref ref-type="fn" rid="FN20">19</xref>), Nikolaus Schultz(<xref ref-type="fn" rid="FN28">27</xref>), Ron Bose(<xref ref-type="fn" rid="FN52">51</xref>), Andy Chu(<xref ref-type="fn" rid="FN8">7</xref>), Eric A Collisson(<xref ref-type="fn" rid="FN39">38</xref>), Leslie Cope(<xref ref-type="fn" rid="FN27">26</xref>), Chad J Creighton(<xref ref-type="fn" rid="FN41">40</xref>), Gad Getz(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN5">4</xref>), James Herman(<xref ref-type="fn" rid="FN27">26</xref>), Bruce E Johnson(<xref ref-type="fn" rid="FN6">5</xref>), Raju Kucherlapati(<xref ref-type="fn" rid="FN11">10</xref>,<xref ref-type="fn" rid="FN12">11</xref>), Marc Ladanyi(<xref ref-type="fn" rid="FN29">28</xref>, <xref ref-type="fn" rid="FN31">30</xref>), Christopher A Maher(<xref ref-type="fn" rid="FN52">51</xref>), Gordon Robertson(<xref ref-type="fn" rid="FN8">7</xref>), Chris Sander(<xref ref-type="fn" rid="FN28">27</xref>), Ronglai Shen(<xref ref-type="fn" rid="FN28">27</xref>), Rileen Sinha(<xref ref-type="fn" rid="FN28">27</xref>), Andrey Sivachenko(<xref ref-type="fn" rid="FN2">1</xref>), Roman K Thomas(<xref ref-type="fn" rid="FN57">56</xref>, <xref ref-type="fn" rid="FN93">92</xref>, <xref ref-type="fn" rid="FN94">93</xref>), William D Travis(<xref ref-type="fn" rid="FN42">41</xref>), Ming-Sound Tsao(<xref ref-type="fn" rid="FN50">49</xref>), John N Weinstein(<xref ref-type="fn" rid="FN33">32</xref>,<xref ref-type="fn" rid="FN35">34</xref>), Dennis A Wigle(<xref ref-type="fn" rid="FN61">60</xref>), Stephen B Baylin(<xref ref-type="fn" rid="FN27">26</xref>), Ramaswamy Govindan(<xref ref-type="fn" rid="FN52">51</xref>), and Matthew Meyerson(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN6">5</xref>,<xref ref-type="fn" rid="FN7">6</xref>)</p>
            </sec>
          </sec>
        </app>
      </app-group>
    </back>
    <floats-group>
      <fig id="F1" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <title>Significantly mutated genes in lung SqCC</title>
          <p>Significantly mutated genes (q-value &lt;0.1) identified by exome sequencing are listed vertically by q-value. The percentage of lung SqCC samples with a mutation detected by automated calling is noted at the left. Samples displayed as columns, with the overall number of mutations plotted at the top and samples arranged to emphasize mutual exclusivity among mutations.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms392594f1.jpg"/>
      </fig>
      <fig id="F2" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <title>Somatically altered pathways in squamous cell lung cancer</title>
          <p><bold>Left,</bold> Alterations in oxidative response pathway genes by somatic mutation as defined by somatic mutation, copy number alteration or up- or down-regulation. Frequencies of alteration are expressed as a percentage of all cases, with background in red for activated genes and blue for inactivated genes. <bold>Right,</bold> Alterations in genes that regulate squamous differentiation, as defined in the left panel.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms392594f2.jpg"/>
      </fig>
      <fig id="F3" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <title>Gene expression subtypes integrated with genomic alterations</title>
          <p>Tumors are displayed as columns, grouped by gene expression subtype. Subtypes were compared by Kruskal-Wallis tests for continuous features and by Fisher’s exact tests for categorical features. Displayed features displayed showed significant association with gene expression subtype (<italic toggle="yes">P</italic>&lt;0.05), except for <italic toggle="yes">CDKN2A</italic> alterations. deltaN expression percentage represents transcript isoform usage between the <italic toggle="yes">TP63</italic> isoforms, deltaN and tap63, as determined by RNA-sequencing. Chromosomal instability (CIN) is defined by the mean of the absolute values of chromosome arm copy numbers from the GISTIC<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> output. Absolute values are used so that amplification and deletion alterations are counted equally. Hypermethylation scores and iCluster assignments are described in <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure S6.1 and S7.A1</xref>, respectively. CIN, methylation, gene expression, and deltaN values were standardized for display using z-score transformation.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms392594f3.jpg"/>
      </fig>
      <fig id="F4" orientation="portrait" position="float">
        <label>Figure 4</label>
        <caption>
          <title>Multi-faceted characterization of mechanisms of <italic toggle="yes">CDKN2A</italic> loss</title>
          <p><bold>a,</bold> Schematic view of the exon structure of <italic toggle="yes">CDKN2A</italic> demonstrating the types of alterations identified in the study. The locations of point mutation are denoted by black and green circles. <bold>b,</bold>
<italic toggle="yes">CDKN2A</italic> expression (y-axis) versus <italic toggle="yes">CDKN2A</italic> copy number (x-axis). Samples are represented by circles and colored-coded by specific type of <italic toggle="yes">CDKN2A</italic> alteration. <bold>c,</bold> Diagram of the <italic toggle="yes">KIAA1797-CDKN2A</italic> fusion identified by whole genome sequencing. <bold>d,</bold>
<italic toggle="yes">CDKN2A</italic> alterations and expression levels (binary) in each sample.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms392594f4.jpg"/>
      </fig>
      <fig id="F5" orientation="portrait" position="float">
        <label>Figure 5</label>
        <caption>
          <title>Alterations in targetable oncogenic pathways in lung SqCCs</title>
          <p>Pathway diagram showing the percentage of samples with alterations in the PI3K/RTK/RAS pathways. Alterations are defined by somatic mutations, homozygous deletions, high-level, focal amplifications, and, in some cases, by significant up- or down-regulation of gene expression (<italic toggle="yes">AKT3, FGFR1, PTEN</italic>).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms392594f5.jpg"/>
      </fig>
    </floats-group>
  </article>
</pmc-articleset>
